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A B S T R A C T  
 
 It is estimated that in 2016, more than 848,000 new cases of cancer will be 
diagnosed in men with more than a quarter being prostate cancer and more than 26,000 
deaths attributed to this disease. Prostate cancer poses a limited risk when detected at an 
early stage and treatment of stages II-III has a 5-year survival rate of almost 100%. 
However, these early-stage cancers can eventually progress and develop into stage IV, 
dramatically dropping the 5-year survival rate to 28%. Thus, development of a new therapy 
is needed to fully eliminate these tumors. Combination of heat and chemotherapy improves 
therapeutic efficacy while allowing for reduced dosing of drugs and limiting side effects. 
Localized hyperthermia has been used to enhance the delivery of polymer therapeutics to 
prostate tumors through increased blood flow, vascular permeability, and incorporation of 
heat shock targeting. This strategy has been shown to increase the delivery and retention 
of polymer-drug conjugates leading to enhanced efficacy. Although much work has been 
done using this strategy, the effects of different thermal dosing on polymer accumulation 
are unknown. The first aim of this research is to examine how altering heating parameters 
influences polymer tumor accumulation. The hypothesis for this aim is that there is an 
optimal thermal treatment that leads to the maximal amount of polymer accumulation in 
the tumors. Additionally, the previously used heating method of plasmonic photothermal 
therapy (PPTT) can result in long-term accumulation of gold nanoparticles in healthy 
organs, potentially limiting clinical applicability. The second aim of this proposal will be 
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focused on investigating the alternative method of high intensity focused ultrasound 
(HIFU) for selective heating of tumors and enhancing macromolecular delivery. HIFU has 
shown the capability for precise, noninvasive heating of specific regions within the prostate 
through magnetic resonance imaging (MRI) guidance. The hypothesis to be tested in this 
aim is that mild hyperthermia produced with HIFU will have the same effect as that 
produced by PPTT in improving the delivery of macromolecular systems to solid tumors. 
Finally, in the third aim, the enhanced delivery of targeted polymer therapeutics to prostate 
tumors in mice models will be investigated using mild hyperthermia produced with HIFU. 
In the long term, it is anticipated that HIFU can be used in conjunction with delivery of 
polymer-drug conjugates for enhanced efficacy and reduced toxicity of chemotherapy to 
produce a clinically relevant treatment of advanced prostate cancer. 
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Prostate cancer is the most common type of cancer among men in the United States 
[1]. Many of these tumors can be treated surgically, but only if detected at an early stage 
[2]. In advanced stages of the disease (stage II-III) the ability to remove the tumor may not 
be available. Alternative methods including radiotherapy, hormone therapy, and ablative 
therapies are used to shrink or eliminate the tumor but have the risk of complications. While 
the 5-year survival rate for stage II-III is close to 100%, the chance for disease progression 
and metastasis is 50% [3]. Once the cancer reaches stage IV, the 5-year survival rate 
dramatically drops to 28% [1]. Current treatments do not adequately eliminate late-stage 
prostate cancers and leave the patient at high risk. Due to the inherent genetic instability of 
cancers, insufficient disease elimination can lead to the development of treatment 
resistance [4]. This potential issue highlights the need to develop a new therapy that fully 
eradicates late-stage prostate cancer before the risk of developing metastases. 
Combination therapy can be a more effective treatment while reducing side effects. 
One such therapy that shows potential is a combination of chemotherapy and hyperthermia. 
Synergistic effects of heat and certain chemotherapeutics, including docetaxel, have shown 
enhanced efficacy [5-7]. In this therapy, the effects of a single dose of the drug can be
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mediated by a fraction of the typical dose in combination with localized hyperthermia. To 
create this effect, localized heating of the tumor should be achieved in conjunction with the 
delivery of chemotherapeutics. 
Localized delivery of hyperthermia also initiates vascular effects that enhance 
accumulation of macromolecular drug conjugates. Mild hyperthermia within the tumor 
increases blood flow and vascular permeability as blood vessels expand to dissipate excess 
heat [8-10] allowing accumulation of macromolecular drug conjugates to a greater degree. 
The macromolecular drug carriers N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymers improve solubility of hydrophobic drugs by increasing their size to prolong 
blood circulation half-life by evasion of renal filtration, and taking advantage of the 
enhanced permeability and retention (EPR) effect to improve tumor accumulation. These 
polymeric carriers also change the mode of entry into cancer cells from diffusion to 
endocytosis allowing for better treatment of drug-resistant cancers [11]. HPMA 
copolymers are further advantageous in their multifunctionality for attachment of imaging 
agents and targeting moieties. 
Mild hyperthermia induces effects at the cellular level including up-regulation of 
cell surface heat shock protein (HSP) receptor glucose regulated protein 78 (GRP78) which 
can be targeted [12]. The heat shock (HS)-targeting strategy relies on the induction of these 
receptors following hyperthermia and allows for site-specific targeting within the heated 
tumor. Targeting these receptors in combination with hyperthermia leads to enhanced 
uptake by receptor-mediated endocytosis. When HPMA copolymer-drug conjugates are 
targeted towards GRP78, retention is prolonged within heated tumor tissue in vivo [12]. 
Comparison of accumulation over time shows that targeted and untargeted systems had 
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significantly more tumor accumulation when using hyperthermia. At later times, the 
untargeted copolymers diffused back out of the tumor returning to the same level as tumors 
left untreated, whereas HS-targeted copolymers retained a larger portion of the copolymers. 
These results demonstrate that the HSP targeting strategy combined with hyperthermia 
increases the delivery and retention of HPMA copolymers. With this combination therapy, 
we can minimize drug dose, reduce systemic side effects, increase and prolong 
accumulation, and eliminate the advanced localized disease.  
Over the past few years, the Ghandehari lab has demonstrated that gold nanorod 
(GNR)-mediated plasmonic photothermal therapy (PPTT) can be utilized to deliver 
localized hyperthermia, increase delivery of HPMA copolymers, and utilize HS-targeting 
to result in synergistic effects in prostate cancer models [13]. This strategy increases the 
overall accumulation of Evans blue dye (EBD), HPMA copolymer conjugates [12,14], 
tumor penetration [15], and improves the therapeutic efficacy of prostate cancer treatment 
[13,16]. GNR-mediated PPTT is a method of heating tumors selectively through absorption 
of near-infrared (NIR) laser light by the GNRs previously accumulated in the tumor tissue. 
In these previous studies, tumors were treated with mild hyperthermia (43°C for 10 min 
determined as a single point measurement via needle thermocouple) which was first shown 
to maintain the temperature within the tumor at 42-43°C and enhance macromolecular 
delivery through increased accumulation of EBD at 5 h post treatment [14]. PPTT was 
additionally shown to improve delivery of untargeted and HS-targeted HPMA copolymers 
[12]. In these studies, it was shown that untargeted polymer accumulation after PPTT leads 
to a transient increase in accumulation peaking at 4 h and returning to baseline at 8 h post 
treatment [12]. With the incorporation of HS-targeting, the enhanced accumulation was 
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retained over longer periods of time [12]. The enhanced accumulation was additionally 
visualized by magnetic resonance imaging (MRI). These experiments showed that PPTT 
could also increase the penetration of HPMA copolymers within the tumor tissue [15]. 
Finally, the enhanced accumulation and penetration was examined with chemo- and radio-
therapeutic copolymer conjugates. Efficacies of HS-targeted and untargeted HPMA 
copolymer-docetaxel conjugates were shown to be significantly improved over free drug 
alone with improvements in synergy as well [13]. Additionally, 90Yttrium was chelated to 
HPMA copolymers and used in conjunction with PPTT [16]. The efficacy of these 
conjugates was also greatly improved. 
In each of these experiments, the same heat treatment was used to improve the 
delivery and enhance treatment in preclinical prostate cancer models. Limited information 
is available on the role of varying heating parameters (temperature and duration) of PPTT 
and the effects on HPMA copolymer accumulation, retention, and consequently efficacy. 
The thermal dose used may not, in fact, be the optimal treatment for delivering maximal 
amounts of polymer conjugates to the tumor site. It is unknown how altering the heating 
regimen will, in turn, alter the polymer accumulation profile. Therefore, it is of interest to 
investigate if conjugate accumulation could be further optimized for maximal enhancement 
with the use of different heating parameters. 
Although much promising work has been done using PPTT, it is still in the early 
developmental phase toward clinical applicability. PPTT utilizes passive accumulation of 
GNRs to the tumor by the EPR effect to then absorb NIR laser light and generate localized 
heat. The systemic delivery of these GNRs leads to nonspecific accumulation in healthy, 
vital organs [17]. Chronic accumulation in these organs may potentially cause adverse 
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effects which are not fully understood. Accumulation in these organs also limits the 
possibility of additionally applying this strategy for selective treatment of liver cancers. 
Since the GNRs will accumulate throughout the liver, this treatment strategy would not be 
able to distinguish healthy liver from cancerous liver tissues. PPTT also only has a depth 
penetration of approximately 1-2 cm further limiting the application of this heating method 
to superficial tumors or otherwise requires the use of a fiber optic probe to reach deep-
seeded tumors. Finally, there will be absorption of laser light in the surrounding healthy 
tissues. This absorption has the potential to cause collateral damage leading to severe side-
effects such as incontinence in prostate cancer treatments. Therefore, it would then be 
advantageous to deliver heat specifically to the tumor tissue by a noninvasive technique 
which also has a larger depth penetration and greater precision of treatment.  
Therapeutic high intensity focused ultrasound (HIFU) can be used to noninvasively 
heat tissues, causing hyperthermia and guide polymer delivery [18]. Currently, clinical 
trials are being performed using transrectal HIFU to ablate prostate cancer tumors [19]. 
This noninvasive ablative therapy could potentially be altered for use in our combination 
therapy. The noninvasive delivery of hyperthermia specifically to the tumor site will 
minimize the risk of complications and the combination therapy will eliminate the risk of 
inadequate tumor treatment, which can lead to possible resistant cancers and risk of 
recurrence.  
 
1.2 Aims and scope of this dissertation 
In prostate cancer, once the tumor has spread and metastasized, the 5-year survival 
rate dramatically drops. To alleviate this problem, a treatment needs to be available to not 
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only slow progression of the late-staged disease but completely eliminate the tumor before 
metastasis. Targeted drug delivery specifically to the tumor using polymeric carriers shows 
promise. A challenge is limited accumulation in solid tumors. Recent studies in the 
Ghandehari lab, using heat specifically delivered to the tumor site, have shown increased 
accumulation of a potent chemotherapy in the form of HS-targeted N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates within prostate 
tumors. In this previous work, heating was achieved through gold nanorod (GNR)-
mediated plasmonic photothermal therapy (PPTT) at mild hyperthermic conditions (43°C 
for 10 min) to enhance the delivery of HPMA copolymer conjugates. Currently, there is a 
lack of understanding on how altering heating parameters (temperature and duration) will 
affect HPMA copolymer accumulation and retention. Additionally, systemic delivery of 
GNRs in PPTT results in significant accumulation in the liver and spleen leading to 
questions about long-term effects potentially limiting clinical translation and use for 
selective heating of liver cancers. Finally, PPTT can lead to collateral tissue damage from 
laser light alone and has limited depth penetration requiring the use of a fiber optic cable 
to reach deep-seeded tumors. Therefore, other noninvasive, more precise, and clinically 
acceptable heating methods need to be investigated to avoid problems and improve the 
applicability of this combination therapy. One such method is high intensity focused 
ultrasound (HIFU). Advantages of using HIFU instead of PPTT include noninvasive 
application and improved precision and depth penetration. In addition, HIFU is currently 
FDA approved to be used in several clinical applications. The goal of this project is first to 
examine the effects of altering PPTT heat dosing on polymer accumulation and second 
investigate the utility of HIFU to induce mild hyperthermia and enhance delivery of 
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targeted polymer-drug conjugates to prostate tumors. The hypotheses to be tested are that 
altering the thermal dose of PPTT can lead to optimized polymer tumor accumulation, 
HIFU can be used to selectively heat tumors at mild hyperthermic conditions and enhance 
macromolecular delivery, and combination with targeted polymer-drug conjugates will 
lead to an improved therapeutic outcome. To test this hypothesis, three Specific Aims were 
pursued as outlined in Sections 1.2.1, 1.2.2, and 1.2.3. 
 
1.2.1 Examine the effects of heating temperature and duration by GNR-mediated  
PPTT on copolymer accumulation in tumor tissue  
This study elucidated the conditions for the maximal accumulation of polymer-drug 
conjugates using PPTT. Four different temperatures (40, 43, 46, or 49°C) and two different 
durations (10 or 30 min) were examined and accumulation of untargeted HPMA 
copolymers in a mouse sarcoma model was initially observed at 4 h post treatment. 
Additionally, the polymer accumulation profile was observed over 8 h for select groups 
that had unexpected accumulation at 4 h. Finally, histological analyses were used to 
examine changes within the tumor tissue due to heating with different thermal doses. 
Untargeted radiolabeled HPMA copolymers were used to track polymer accumulation in 
vivo. The polymers remained untargeted for these experiments since the goal was to 
examine the thermal effects and HS-targeting would further complicate the system. 
Accumulation studies were performed in CD1 mice bearing S-180 sarcoma tumors as they 
are known to exhibit the EPR effect for passive accumulation of GNRs and observe 
augmentation of this effect with hyperthermia without the need of an immune 
compromised mouse strain. The temperatures were chosen in increments of 3°C starting 
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from 43°C as this was used in prior experiments and initially chosen to be consistent with 
other literature methods [12-16]. It is widely considered that temperatures above 46°C are 
thermoablative [20], but also depends on time spent at the given temperature. Therefore, 
one temperature at 46°C and one above (49°C) was selected. Finally, one temperature 
lower than 43°C was selected to observe how longer durations could affect treatments with 
lower temperatures (40°C).  
 
1.2.2 Investigate HIFU as an alternative heating method for inducing mild  
hyperthermia and enhancing macromolecular delivery to tumors 
HIFU parameters (focal spot pattern, speed, and power) were optimized with the 
development of a feedback controller to achieve mild hyperthermia using a tumor phantom 
and then translated to an in vivo tumor model. Temperature distribution was imaged by 
MRI. The capability for HIFU to enhance macromolecular delivery was determined by 
Evans blue dye (EBD) and Gadolinium-labeled HPMA copolymer tumor accumulation. 
To evaluate the controller performance, the parameters of HIFU were first tested ex vivo 
using a tumor phantom model. For these experiments, chicken breast was used in 
preliminary studies as its acoustic and thermal properties are well known [21,22] and can 
be translated to an in vivo tumor model. In order to account for the variabilities seen in 
vivo, a feedback controller was developed to use MR thermometry data to automatically 
adjust the HIFU parameters to heat and maintain the tumor at 43°C. Once this set of 
experiments was completed, accumulation studies using HIFU as the heating method was 
performed with EBD and gadolinium (Gd)-labeled copolymers for visualization of tumor 
accumulation by MRI. These studies were performed in the CD1 mouse S-180 tumor 
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model to observe an enhancement of macromolecular delivery and allow for comparison 
to previous experiments that were done with PPTT [14].  
 
1.2.3 Determine the capability for HIFU to improve efficacy of  
HS-targeted polymer-drug conjugates 
The ability for HIFU to induce up-regulation of HSPs was determined by histology, 
and enhanced in vivo efficacy of targeted polymer-drug conjugates was determined by 
tumor regression and immunohistochemical analyses for molecular characterization of 
efficacy. In these experiments, the animal model used was nu/nu mice bearing DU145 
prostate tumors to compare to previous efficacy experiments done with PPTT [12,13,16]. 
Untargeted and targeted copolymer-docetaxel conjugates were used in combination with 
and without HIFU to observe changes in the efficacy of treatment, as well as cytotoxic 
effects. Copolymer-docetaxel-drug conjugates that showed synergism with HS-targeting 
using PPTT [13] were used in these studies.  
The following chapters of this dissertation describe the experimental work used to 
complete the presented aims. A comprehensive literature review of hyperthermia 
approaches to enhance delivery of nanomedicines to solid tumors is presented in Chapter 
2 and reviewed elsewhere [23]. Chapters 3 [24], 4 [25], and 5 [26] present the methods, 
results, and discussions addressing Specific Aims 1-3. Chapter 6 outlines the conclusions 
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Despite the latest technological advances in cancer therapies, a significant impact 
on survival rates has not been observed from improved treatments alone [1]. Changes in 
survival can largely be argued to be based on biases created from early detection through 
increased lead-time bias, length bias, and overdiagnosis. There are still many challenges to 
developing treatments that fully eradicate this complex disease. One such challenge is to 
overcome barriers to the delivery of drugs or other therapeutic agents to the tumor site. 
Many conventional chemotherapeutic drugs lack significant accumulation at the tumor site 
where only less than 1% of the injected dose (ID) is localized [2]. This phenomenon can 
be broken down into a few different aspects including poor water solubility of drugs, short 
circulation half-life (on the scale of only a couple hours), and the physiological barriers 
that exist within the tumor limiting extravasation and penetration into the tissue [3]. These 
barriers include growth induced solid stresses, dense interstitial structure, elevated  
interstitial fluid pressures, and abnormal blood vessel networks [3]. Accumulation can be 
improved through the use of nanomedicine formulations, but the amount delivered to the 
Reprinted in part with permission of Wiley. N. Frazier, H. Ghandehari. Hyperthermia 
approaches for enhanced delivery of nanomedicines to solid tumors. Biotechnology and 




tumor still remains low at <5% ID [2]. Additionally, the administration of drugs 
systemically through intravenous (IV) injection can result in an undesirable biodistribution 
leading to accumulation within healthy vital organs causing harmful side-effects and 
toxicity. These adverse effects can limit dosing of chemotherapy due to concerns for patient 
safety and leads to the patient potentially going untreated allowing the cancer to continue 
to grow. To help resolve the problems of low tumor accumulation and systemic toxicity, 
many nanoparticle systems have been developed to enhance the delivery of 
chemotherapeutic drugs to the tumor site as well as target the tumor specifically to avoid 
or limit off-target accumulation and dose-limiting toxicity. 
A variety of nanoparticles have been developed for targeted drug delivery to solid 
tumors. These can broadly be categorized as inorganic [4] and organic [5] nanoparticles. 
Inorganic nanoparticles investigated for drug delivery to solid tumors include, but are not 
limited to, gold [6-8], magnetic [9-11], and silica-based nanoparticles [12]. Organic 
nanoparticles include, but are not limited to, synthetic polymeric systems such as linear 
water soluble polymers [13-17], branched macromolecules such as dendrimers [18], 
amphiphilic micellar structures [19-22], lipid-based particles such as liposomes [23], and 
natural carriers such as albumin [24, 25]. Figure 2.1 represents a few examples of some of 
the nanoparticles used for drug delivery.  
Associating drugs with any type of nanoparticle formulation alters the 
pharmacokinetic properties of the drug. For example, accumulation in the tumor of drug 
containing liposomal, micellar, and polymeric delivery systems is generally higher 
compared to free drugs [19, 20, 26-28]. This is largely due to extravasation through the 







Figure 2.1: Examples of different nanoparticle types used for drug delivery. Inorganic 
nanoparticles include gold, magnetic, and silica-based systems. Organic nanoparticles 
include linear polymers, hyperbranched dendrimers, micelles, liposomes, cross-linked 
nanogels, and natural polymers. 
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lymphatic system exploiting the enhanced permeability and retention (EPR) effect, as well 
as lowering systemic toxicity [29, 30]. 
The majority of nanoparticles investigated for cancer treatment exploit the EPR 
effect [29-33]. The EPR effect arises within many solid tumors due to the unique structural 
features during vascular formation. Blood vessels are irregularly shaped and undergo 
sprouting, proliferation, remodeling, and regression [31]. The tumor vascular network 
lacks normal hierarchical arrangement and includes hyper-vasculature, defective vascular 
architecture, and impaired lymphatic drainage [30, 31, 34]. The resulting blood vessels can 
have large pore sizes that allow for the passive accumulation of nanoparticles leading to 
extravasation from the blood supply while being retained from the lack of functional 
lymphatics [32, 35]. In contrast to low molecular weight molecules (i.e., free drug), 
nanoparticles large enough to avoid renal filtration circulate throughout the body 
(circulation half-life) on the scale of several hours up to one day rather than a period of 
only a few minutes for commonly used chemotherapeutics [36]. This prolonged circulation 
leads to more accumulation in the tumor by the EPR effect [33]. However, there is 
significant heterogeneity within and between tumor types [37]. Heterogeneity of tumors 
can lead to differences in vascular pore dimensions and EPR based on tumor size, type, 
location, and extent of macrophage infiltration and activity of the mononuclear phagocytic 
system [37]. The heterogeneity of the EPR effect in solid tumors may contribute to the 
limited impact of nanoparticle conjugated drugs [37]. Additionally, the impact of 
nanomedicines has been limited by clearance and sequestration by the mononuclear 
phagocyte system (MPS) and kidneys eliminating >90% of administered nanoparticles 
from the blood supply [38].  
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Despite a large investment over the last 30 years toward the development of 
nanomedicines to selectively treat cancer, significant clinical translation has not been 
observed [38]. Passive targeting by the EPR effect has been the foundation of many 
nanomedicines designed to increased anticancer activity and lower toxicity [39]. However, 
only very few nanosystems based on this principle have had success in the clinic [39]. This 
may be due to several key differences between human and murine tumors accounting for 
the disparity between preclinical and clinical trial results of most drug carriers [40]. Human 
tumors can have numerous causes, where the right set of mutations are required to initiate 
uncontrolled proliferation undergoing a process of elimination, equilibrium, and escape 
that can often take years [40]. Murine tumors are more apt to be subject to research 
constraints and generally developing tumors within a few weeks instead of years. During 
this growth process, angiogenesis must occur at a rapid pace making the blood vessel 
structure particularly disorganized, hyperpermeable, and exhibit EPR [40]. Lastly, the large 
tumor-to-body weight ratio in mice as compared to human patients may also significantly 
alter the pharmacokinetics of drug carriers. Human tumors tend to be no more than a few 
grams in weight, giving it an insignificant share of the total body weight of the patient, 
whereas murine tumors are often grown to be as much as 10% of the mouse's body weight. 
Such large tumors filter a significant portion of the injected dose of the nanomedicine, 
effectively improving the accumulation and efficacy while mitigating the toxicity. 
Therefore, with these revelations, it seems that targeting tumor tissue by EPR alone likely 
will not achieve improved efficacy in humans and other strategies besides passive targeting 
must be considered to enhance delivery. 
Alternative strategies to enhance delivery include augmentation of the EPR effect 
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with the use of vascular mediators as well as heat treatment with mild hyperthermia to 
increase blood flow and vascular permeability in the heated tumor tissue [41]. Vascular 
mediators can be used to increase the blood pressure during infusion of the nanomedicine 
with certain mediators [37]. However, hyperthermia has the capability to be controlled over 
time and can additionally create other beneficial effects for the treatment of cancer. The 
focus of this chapter is on the use of hyperthermia to enhance the delivery of nanomedicines 
to solid tumors.  
 
2.2 Hyperthermia to enhance delivery 
The EPR effect can be augmented in a number of ways to enhance the delivery of 
nanomedicines to solid tumors. One such method that has shown great promise for 
improving localization, penetration, and targeting effects of nanomedicines to solid tumors 
is through the generation of heat within the tumor. Hyperthermia can be applied in a variety 
of ways for cancer treatment, each with their own advantages and disadvantages. 
Hyperthermia in cancer treatment is defined as the generation of heat generally 
between temperatures of 41°C and 46°C [42]. Mild or moderate hyperthermia is considered 
to be 41-43°C, whereas severe hyperthermia is at 44-46°C [42]. When the tumor is 
subjected to temperatures > 46°C, this is considered to be thermoablation, causing cells to 
undergo direct tissue necrosis, coagulation, or carbonization [43]. Hyperthermia can be 
applied to either heating the entire body, a region of the body, or selectively heating of a 
solid tumor only [44]. Of these, local hyperthermia is gaining much more attention than 
whole body or regional hyperthermia where various techniques are being developed to 
deliver heat to the tumor specifically [42, 43]. In this review, we will focus our discussion 
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on modalities used for local therapies. The challenge for these treatments is to 
noninvasively heat only the tumor cells without damaging the healthy tissues where 
complications can occur.  
Localized hyperthermia has particularly been used as an adjuvant with chemo- or 
radio-therapy for the treatment of primary tumors and early stage cancers as these tumor 
cells are considered to be more susceptible to hyperthermic effects [45]. Biological tissues 
exposed to higher than normal temperatures promote the selective destruction of these 
abnormal cells [45]. Hyperthermia leads to several physiological changes within the heated 
tumor tissue (Figure 2.2). At the vascular level, these include increased blood flow, 
vasodilation, and enhanced permeability [41]. This can, in turn, alter pH and oxygenation 
of the tumor microenvironment. Hyperthermia also affects cellular processes through 
protein denaturation, protein folding, aggregation, and deoxyribonucleic acid (DNA) cross-
linking leading to disruption of biomolecular assemblies, induction of heat-shock proteins, 
and also disruption of cellular mechanisms promoting the onset of acidosis or apoptosis 
[43, 45].  
 
2.3 Combination effects of hyperthermia 
Hyperthermia can be used in cancer therapies both to enhance the delivery of 
specific carriers, or nanomedicines, as well as enhance the efficacy of therapeutic agents. 
These heat treatments complement currently available therapies such as chemotherapy, 
radiation therapy, gene therapy, immunotherapy, and surgery [44]. Oncologists have often 
used the heat treatment in combination with radiotherapy and/or chemotherapy [46, 47]. 

















Figure 2.2: Vascular and cellular effects of hyperthermia on heated tumor tissue. Vascular 
effects include increased blood flow, vascular permeability, and vasodilation. Cellular 




main effects leading to synergistic effects with chemotherapy and radiation treatments [48]. 
Blood flow within the tumor is highly irregular and poses several challenges as we 
discussed earlier. However, evidence suggests that hyperthermia can be effective in 
improving flow throughout these tumors that can overcome some of the biological barriers 
to delivery when significant localized heating is achieved. Increases in blood flow and 
accumulation have been observed both during and after hyperthermia [49, 50]. 
Combined approaches with hyperthermia result in a more effective elimination of 
many cancer cells in addition to making resistant cells more vulnerable to these treatments 
[51]. Moderate increases in temperature sensitize cancer cells to cytotoxic agents by 
increasing the permeability of tumor vasculature and cell membranes and lowering 
hydrostatic pressure. In addition, hyperthermia can render tumor cells temporarily more 
sensitive to the damaging effects of radiation or chemotherapeutics through cellular 
mechanisms. An important effect of hyperthermia is the inhibition of DNA repair [48]. 
Hyperthermia results in protein unfolding that, if not chaperoned properly by heat shock 
proteins (HSPs), can lead to irreversible toxic protein aggregates and ultimately leading to 
apoptosis [52]. It has been shown though that different cell lines exhibit different 
sensitivities to hyperthermia as this aspect is mostly due to differences in recovery from 
heat shock [51]. Inducing hyperthermia above a certain threshold temperature (>46°C) is 
more likely to induce necrosis than apoptosis [51].  
Hyperthermia is a promising mode of adjuvant cancer therapy intended to enhance 
the efficacy of traditional therapies of chemo- and radio-therapy [50]. The synergistic 
effects of hyperthermia have been studied in cell cultures, animal models, and clinical trials 
[47]. However, clinical adoption of hyperthermia faces limitations such as the challenge of 
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localizing heat only to the tumor site and the reduced effectiveness of heating in cancer 
cells that have developed thermotolerance from up-regulated HSP expression. Modern 
clinical hyperthermia trials focus mainly on optimizing of thermal homogeneity with 
moderate temperatures in the target volume using noninvasive methods, a problem which 
requires extensive technical efforts for development of advanced treatment and 
thermometry systems [42].  
In the continuous search for cancer therapies with a high therapeutic index (ratio of 
the amount of a therapeutic agent that causes the therapeutic effect to the amount that 
causes toxicity), localized temperature-induced drug delivery may offer a breakthrough 
solution in minimally- or noninvasive treatments of cancer. This multidisciplinary 
approach has evolved from recent advances in pharmaceutical chemistry, nanoscience, 
hyperthermia technologies, and clinical research with the potential to provide an efficient 
and patient-friendly treatment option under image guidance.  
Several different methods for producing heat in cancer treatments have been 
developed using alternative energy sources to induce heating. Currently, available 
techniques to produce heat use external devices such as laser irradiation and 
electromagnetic currents aided with or without nanoparticles aimed to improve localized 
heating. Additionally, radiowaves and ultrasound have been used to generate heat but 
without nanoparticle transducers. Still, limitations exist where incidental heating of healthy 
tissue can result in burns and discomfort, limited depth of penetration, and insufficient 
heating of the target region yielding incomplete treatment and recurrent tumor growth [43]. 
To solve problems of limited penetration depth, one approach has been to insert minimally 
invasive devices such as antennas or optic fibers directly within or near the tumor, but this 
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approach is restricted only to locations that are readily feasible for insertion (e.g., head and 
neck, prostate, liver, and renal) [53]. 
In the following section, the methods of heating are further detailed and their 
advantages and disadvantages for the treatment of cancers with localized heating are 
highlighted. All of these methods have the ability to be used for any type of localized 
heating mentioned above (hyperthermia or thermoablation) depending on the intensity at 
which they are applied and the desired outcome. 
 
2.4 Methods of local heat generation for treatment of cancer 
2.4.1 Photothermal therapy 
Laser light alone can be used to treat cancer by creating heat energy leading to the 
destruction of the cancer tissue [54-56]. One of the limitations of using laser alone, 
however, is the nonspecific absorption in surrounding tissues requiring more energy to 
adequately treat the tumor site and subsequently causes burning, blistering, and pain. 
Improvements to heat delivery are required to reduce these effects and create specificity of 
heat generation, homogeneous heat distribution, and therapeutic temperatures in the deep 
regions of tumors [57]. A common method that has been practiced to improve the depth of 
penetration and improve selective heating is to use gold nanoparticles (GNPs) specifically 
synthesized to exhibit plasmonic properties and absorb near-infrared (NIR) wavelengths 
[45]. Laser irradiation at NIR frequencies can penetrate tissues with sufficient intensity and 
higher spatial precision for inducing localized hyperthermia [45]. NIR light has the largest 
depth penetration through most human tissues as blood and soft tissues are relatively 
transparent allowing light to pass while being weakly absorbed [58, 59]. This region of 
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light can penetrate several centimeters through tissue and greatly depends on the tissue it 
travels through [59, 60]. While the light propagation occurs in the tissues, effective 
mechanisms are then needed to transform the light energy into heat and discriminate 
unhealthy from healthy cells. 
Over the last decade, many research groups have focused on developing novel gold 
nanostructures to achieve surface plasmon resonance (SPR) in the NIR region. GNPs 
exhibit SPR at certain wavelengths and when the light is directed to the particles, the SPR 
causes oscillations of the particles’ electron cloud which converts the absorbed light into 
heat energy [61, 62]. This mechanism can be used to sensitize the tumor tissue for light 
absorption where it would not have occurred otherwise. In particular, GNP optical 
properties and flexible surface chemistry permit their use in plasmonic photothermal 
therapy (PPTT) treatments. Plasmonic gold nanostructures thus show great promise for the 
selective PPTT of cancer as well as other diseases [63]. The different gold nanostructures 
that have shown this property include nanoshells [64-68], nanorods [45, 57, 62, 69, 70], 
and nanocages [58, 71-73]. 
Delivery of the nanoparticles specifically to the tumor tissue becomes important for 
successful treatment. The efficiency of delivering GNPs can be enhanced by exploiting 
EPR effect to concentrate particles in solid tumors. However, as discussed above, this may 
not be applicable to all tumors as there can be heterogeneity in vascularity in these tissues 
[37]. The addition of active targeting strategies has been utilized to potentially increase the 
delivery of GNPs to the tumor tissue in order to reduce the required laser power for PPTT 
and minimize collateral damage to surrounding healthy tissues [58]. Still, these strategies 
have not achieved this desired effect and the opposite effect was observed by reduced 
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accumulation due to faster elimination from the blood [61, 74]. Further work on methods 
to evade the immune system with these targeted carriers needs to be considered. Targeting 
to particular tissues can be complicated by possibly inducing interactions with immune 
cells leading to off-target accumulation in filtration organs such as the liver and spleen 
[61]. The long-term accumulation in these organs is observed even without conjugation of 
targeting moieties and the side effects over time are still not fully understood limiting their 
application in the clinic.  
Gold nanoshells can be tailored to absorb NIR light and serve as a photothermal 
therapeutic strategy [69]. Halas et al. have developed 10 nm thick gold nanoshells 
supported on 110 nm diameter silica cores with a NIR absorption peak and demonstrated 
their use in photothermal ablation of cancer cells and tissues [75]. By adjusting the relative 
core and shell thickness, nanoshells can be synthesized to absorb or scatter light at a desired 
wavelength. This optical tunability permits fabrication of nanoshells with a peak optical 
absorbance in the NIR region [76]. These nanoshells were studied for application in 
producing laser-induced thermal effects in tumors delivered through systemic 
administration [65]. Studies have shown that nanoshells absorb NIR light and generate 
increased temperatures sufficient to produce irreversible photothermal damage to 
subcutaneous tumors [64, 65, 68]. Gold nanoshell applications for tumor photothermal 
ablation have advanced considerably in the past few years making their way to clinical 
trials where a single dose pilot study of AuroShell® particles (Nanospectra Biosciences, 
Inc., Houston, TX) was given intravenously to patients with recurrent or refractory head 
and neck cancer for treatment with PPTT [67, 77, 78]. 
Gold nanorods (GNRs) are another type of nanostructure for the application of 
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PPTT-induced hyperthermia. By synthetically varying the aspect ratio of the nanorods, 
longitudinal plasmon absorption can be shifted throughout the visible, NIR, and IR regions 
[79]. The aspect ratio (length: width) that correlates with absorption in this region is 
approximately 4:1. GNRs exhibit significantly narrower line widths than spherical 
nanoparticles and are also highly efficient at converting light energy into heat, with a higher 
absorption cross-section at NIR frequencies per unit volume than most other nanoparticles 
[57]. The absorption cross-section of nanorod structures is shown to be nominally larger 
than that of nanocages and more than twice that of nanoshells at their NIR SPR [80]. GNRs 
perform well as a photothermal device responding to light irradiation because of their 
strong extinction band corresponding to the longitudinal surface plasmon band [62]. The 
region of heat generation in photothermal therapy using GNRs can be confined to tumor 
tissues with high spatial precision because significant heat is generated upon light 
illumination only at the sites where the GNRs are located [57]. 
PPTT studies have additionally been performed using gold nanocages (GNCs). 
GNCs are particularly attractive for additional therapeutic applications from their unique 
hollow structure allowing for drug encapsulation and controlled release [73, 81]. By 
controlling the titrated amount of HAuCl4 in the reaction, the SPR peak position of GNCs 
can be precisely tuned to any wavelength of interest in the range of 600–1200 nm. These 
GNCs strongly absorb at their SPR peak wavelength which can also be tuned to be in the 
NIR region [58]. Studies using GNCs for PPTT have been shown to serve as effective 
transducers converting light energy to heat and effectively treating cancer [73]. These 
particles have been validated in vivo showing photothermal effects were able to decrease 
tumor metabolic activity only observed in tumors treated with the combination of GNCs 
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and laser exposure [73].  
GNPs of different shapes and structures can be synthesized readily and in a tunable 
manner to absorb in the NIR region. The advantages and disadvantages of each structure 
are summarized in Figure 2.3. The NIR light is optimal for penetration through tissues to 
then be absorbed by GNPs previously accumulated in the tumor. With the application of 
these two components in conjunction, they can be used to create tumor-specific heating for 
hyperthermia applications.  
Besides the use of GNPs, other types of nanoparticles have recently been developed 
and used for photothermal therapies. These include Prussian blue nanoparticles [82, 83], 
carbon nanotubes [84, 85], copper sulfides [86-88], and polypyrrole nanoparticles [89]. 
These alternatives to GNPs have also been able to show strong absorption in the NIR 
region. For Prussian blue nanoparticles, an ancient dye made of mixed-valence transition 
metal hexacyanoferrates with the general formula of FeIII4[FeII(CN)6]3·nH2O, the 
argument has been made that they are advantageous in their ease and low cost of synthesis 
and have FDA approval for treatment of radioactive exposure [82, 90]. Comparison to 
GNRs was performed but required larger amounts of Prussian blue nanoparticles in parts 
per million and had a much broader absorption peak [83]. Carbon nanotubes have been 
shown to achieve sufficient heating in vivo [84, 85] and exhibit extraordinary photon-to-
thermal energy conversion efficiency with a high absorption cross-section of NIR light [91] 
but are severely limited by their toxicity and difficulties in synthesis [92]. Copper sulfide 
nanocrystals show high photothermal conversion efficiency similar to that of gold 
nanostructures but exhibit peak absorbance at 900–980 nm rather than 808 nm, the 












Figure 2.3: Nanoparticles for inducing hyperthermia. Advantages and disadvantages of 
gold nanoshells, nanorods, nanocages, and magnetic nanoparticles. 
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nanoparticles for photothermal therapies have not been extensively studied but face a few 
major limitations including very high laser power for nanoparticle activation, not optimized 
synthesis methods for precise control over size and shape as well as surface modification, 
and lack of understanding of in vivo interactions influencing pharmacokinetics, 
reticuloendothelial system (RES) sequestration, and renal clearance [93]. Finally, unlike 
the previously described nanostructures, polypyrrole nanoparticles, formed from a 
conductive organic polymer, show potential as a biodegradable photothermal agent. These 
nanoparticles present a new type of low-cost, biocompatible photothermal agent, with high 
photothermal conversion efficiency and good photostability [89, 94-96]. 
 
2.4.2 Magnetic fluid hyperthermia 
Magnetic nanoparticles (MNPs) are also used for selective induction of heat 
specifically within tumor tissues. This method is called magnetic fluid hyperthermia 
(MFH) and uses MNPs heated by an externally applied alternating current (AC) magnetic 
field [42, 97]. MFH is a minimally invasive method to treat cancer cells through heat and 
offers great promise as an approach for localized hyperthermia [98]. MFH creates an 
increase in temperature from oscillations in the magnetic field which is “absorbed” by the 
MNPs in the tissue. It requires efficient delivery of the MNPs to the tumor site and 
subsequently applying a well-defined AC magnetic field [50]. Similar to PPTT, this 
method leads to heat generation only where the particles reside and requires nanoparticles 
to be previously dispersed throughout the target tissue to produce sufficient, homogeneous 
heating when the AC magnetic field is applied. 
The amount of heat generated depends on several factors including the strength and 
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frequency of the applied magnetic field, particle size and composition, and concentration 
within the tissue [99-101]. Strategies for delivering the particles to the tumor are similar to 
those above for GNPs. To induce hyperthermic temperatures, the strength of the magnetic 
field must be sufficient (3.8 to 13.5 kA/m) [102].  
MFH may offer several advantages over conventional heating techniques especially 
since this method has superior selectivity for heat generation where MNPs reside. The 
magnetic field is not absorbed by surrounding tissues as can be observed with PPTT or 
other energy sources that are absorbed by conductive tissues. In this case, the tissues do 
not interfere with power absorption and only the MNPs absorb the oscillating magnetic 
energy. This therapy has been used in clinical trials and has potential for treatment of a 
variety of cancers including those of the prostate and brain [102]. MFH has also been 
clinically evaluated in patients suffering from pretreated recurrent tumors, where 
hyperthermia in conjunction with irradiation and/or chemotherapy was an option [103]. 
MFH has shown great capabilities for hyperthermia and thermoablative therapies and 
should be considered for treatment of various cancers. 
The use of MNPs to deliver thermal energy by MFH has been under development 
for almost six decades but has still not been able to reach significant clinical application. 
The commercial development of this technology as Nanotherm® has additionally seen 
limited use in the clinic. Much of this has to do with the significant limitations of this 
method attributed to dispersion of MNPs throughout the body from systemic 
administration, lack of homogenous distribution through the tissue for even heating, and 
insufficient delivery of adequate amounts of MNPs to the tumor site [104]. The long-term 
impacts of acute exposures are not well understood and it is plausible that internalized 
31 
 
MNPs may corrode over a long period of time releasing metallic ions that can lead to DNA 
damage [105]. Accumulation in these organs can also lead to heating within undesired 
tissues when the AC field is applied if the field is not focused to the tumor region. 
Aggregation of the particles can affect the heat response leading to ineffective treatment. 
The required amount of MNP tumor accumulation has previously been calculated showing 
that even for optimized systems, a 5 mm diameter tumor would need a concentration of 
approximately 650µg/cm3 [104]. These large amounts of MNPs are needed to accumulate 
locally and uniformly within the tumor tissue to achieve sufficient heating. In order to 
achieve such large amounts of localization, the MNPs must be injected intratumorally and 
which cannot likely be accomplished through IV injection. If this is the case, then the tumor 
location would need to be determined prior and can potentially miss metastatic regions that 
could be located with systemic administration. Finally, for patients that have magnetic 
implants or other implantable devices, this treatment may not be safe for exposure to these 
large magnetic forces. Although the concept of MFH is very intriguing, its limitations are 
largely too great to compete with other methods of hyperthermia.  
 
2.4.3 High intensity focused ultrasound 
High intensity focused ultrasound (HIFU; frequencies greater than 20 kHz) has 
been developed into a technology for local hyperthermia and ablation of pathological and 
cancerous tissues [106, 107]. HIFU is a noninvasive method for producing heat within the 
body through focusing ultrasound beams into a single focal spot. This can be achieved with 
single or multiple element transducers. This phenomenon can then create heating by the 
propagation of ultrasound waves through any type of tissue including bone. When using 
32 
 
multiple-element transducers, the focusing of the beams can take into account the refraction 
and absorption of heterogenous tissues to focus many beams into a single point [108]. 
However, because ultrasound waves cannot propagate through air, it is difficult to apply 
HIFU in regions containing air such as lung or bowel. In addition to being completely 
noninvasive (not requiring a previous injection of nanoparticles), HIFU has a very large 
depth of penetration throughout the body with the possibility of treating most any part of 
the body based on transducer dimensions. HIFU additionally allows for heating with a high 
degree of temporal control, as the rate of heating depends on the magnitude and duration 
of the ultrasound exposure, which can be readily controlled [109]. When performed under 
magnetic resonance imaging (MRI) guidance, the treatment can be enhanced through 
treatment planning and real time monitoring of the tumor temperature. This simultaneous 
imaging guides the treatment and can provide real time feedback [110, 111]. 
One drawback in comparison to the previous methods of heating is that focal zone 
does not preferentially heat the tumor tissue as we have seen with the other nanoparticle 
methods. HIFU has a relatively small, cigar-shaped, focal zone, on the scale of a few 
millimeters (e.g., 1-3 x 3-8 mm), and needs to be moved throughout a larger tumor to 
achieve uniform heating if hyperthermia is the ultimate goal. Electronic beam steering can 
be used in this case using a phased array ultrasound transducer in combination with real 
time temperature mapping by MR thermometry to heat the pathological tissues at a 
predefined temperature over a certain length of time [112]. This MR-guided HIFU 
(MRgHIFU) technology platform is currently being clinically evaluated for thermal 
ablation of uterine fibroids but has also potential applications in temperature-induced local 
drug delivery with mild hyperthermia [113] and other ablative therapies in oncology (i.e., 
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breast, prostate, liver, brain) [114]. Because of these attributes, HIFU has emerged as a 
leading modality for heat-triggered drug delivery applications. As discussed below, for 
combination therapies with nanomedicines, HIFU has been extensively used for targeted 
release of therapeutic payloads from temperature-sensitive liposomes. 
 
2.4.4 Microwaves, radiowaves, other electromagnetic radiation 
Electromagnetic (EM) energies such as microwaves and radiowaves have been 
used to generate heat within tissues including tumors [47]. These types of energy are forms 
of EM waves and fall within the spectrum of ranging wavelengths and frequencies. 
Microwaves include EM waves ranging from one meter to a millimeter with frequencies 
between 300 MHz and 300 GHz while radiowaves are considered to be wavelengths 
ranging from 1 millimeter to 100 kilometers and frequencies from 300 GHz to 3 kHz. These 
types of energy interact with the tissue through charged particle oscillations which gain 
energy within the molecular structure [115]. The energy can be ultimately scattered, 
reflected, or absorbed by heating the material. Superficial tumors can be locally heated by 
means of external antennas or applicators that emit microwaves or radiowaves [53]. Several 
types of applicators exist (e.g., ring, horn, spiral, and current sheet) and have been used in 
preclinical models [46, 116]. Intratumoral temperature is controlled by both the output of 
the power generator and also by the positioning of the applicator [53]. In order to ensure 
sufficiently high temperatures are produced evenly throughout the tumor, multiple 
applicators can be used. This practice can then become very invasive as multiple needles 
are required to be inserted around the tumor. All methods previously described for inducing 
localized hyperthermia are summarized in Figure 2.4. The methods on the right (MFH and 
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PPTT) require a previous injection of nanoparticles whereas those on the left do not (Figure 
2.4). For microwave/radiofrequency application, invasive applicators are required (Figure 
2.4). Lastly, HIFU does not require either to heat tumor tissue shown as the red circle in 
the human outline (Figure 2.4). 
 
2.5 Applications with nanomedicines 
It has been shown that nanoparticles alone have added benefits of reducing toxicity 
while maintaining longer blood circulation and exhibiting controlled release as discussed 
previously. Targeting of different receptors and pathways can be used with these 
nanomedicines to improve selectivity, accumulation, retention, and ultimately efficacy 
[117, 118]. However, the targeting of nanoparticles in many cases does not substantially 
improve localization or targeted release and still has the potential for further improvements 
[119, 120]. Localized hyperthermia is one such strategy that possesses this potential and 
can be applied in combination with any of these nanomedicines to enhance delivery. Also 
further improving the therapy by reducing general toxicity, triggered release through 
thermoresponsive nanomedicines can localize the therapeutic payload in the heated region 
or heated tumor. The latest research using the combination of hyperthermia and 
nanomedicines has demonstrated that this strategy can be used for better treatment of 
localized solid tumors which will be discussed further. Hyperthermia has the ability to 
enhance delivery through increased blood flow and vascular permeability and these 















Figure 2.4: Various methods for inducing hyperthermia. High Intensity Focused 
Ultrasound (HIFU), Magnetic Fluid Hyperthermia (MFH), Microwave/Radiofrequency, 
and Plasmonic Photothermal Therapy (PPTT). 
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2.5.1 Enhanced delivery by exploiting vascular effects 
As mentioned earlier, applying hyperthermia immediately before or during the 
administration of nanomedicines can lead to increased accumulation in solid tumors [121]. 
This approach aims to increase perfusion and vascular permeability leading to favorable 
effects on extravasation in treated tumor areas. To achieve increased perfusion for 
enhancing drug delivery, gold nanoshells have been used to mediate the thermal effects 
[66]. Gold nanoshells were delivered to the tumor site by passive extravasation and 
retention of the circulating nanoshells from the tumor vasculature into the tumor 
interstitium. The temperature rise was monitored in real time using MR thermometry and 
increases in perfusion were measured by MR dynamic contrast-enhanced (DCE) imaging 
to observe changes in perfusion before and after each hyperthermia treatment. These results 
indicate that this nanoshell-mediated heating can be used to improve perfusion and 
subsequently enhance drug delivery [66].  
Recently it was shown that these events can also be induced from GNR-mediated 
PPTT to enhance macromolecular delivery [122]. This method of hyperthermia produced 
the same effects on tumor vasculature and improves extravasation of nanomedicines into 
the tumor tissue. To produce the PPTT hyperthermia, the GNRs were also passively 
delivered to the tumor site through systemic administration and extravasation by the EPR 
effect. The accumulation was allowed to take place over 48 h when maximal concentration 
occurs [122]. Immediately before laser therapy to induce hyperthermia, Evans blue dye 
was injected IV and used to track macromolecular accumulation in the tumor site [122]. 
With the use of PPTT, the enhanced accumulation was improved up to 80% 5 h post 
treatment as compared to untreated tumors (Figure 2.5A). 
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Further, GNR-PPTT hyperthermia was shown to cause up-regulation of cell surface 
expression of HSPs that can be targeted with specific targeting peptides [123]. Also, this 
method of hyperthermia was used to enhance the delivery of water-soluble copolymers of 
N-(2-hydroxypropyl)methacrylamide (HPMA) both in vitro and in vivo [123]. In these 
studies, DU145 prostate cancer cells were used and showed in vitro that combination of 
hyperthermia and heat shock targeting significantly enhanced the cellular uptake of 
targeted copolymers [123]. When examined with in vivo mouse models using nu/nu mice 
and the same prostate cancer cell line, PPTT was applied in the same fashion to produce 
hyperthermia. HPMA copolymer delivery was tracked using 125Iodine radiolabeling and 
was able to show the effects of HSP targeted and untargeted copolymers with and without 
hyperthermia [123]. The results indicated that hyperthermia significantly improved 
untargeted copolymer accumulation over the first 4 h but then returned to baseline 
accumulation of untargeted copolymers without hyperthermia (Figure 2.5B) [123]. Heat 
shock targeting alone slightly improved tumor accumulation but when combined with 
hyperthermia the effects were much greater than any other group improving accumulation 
and retention. It is suggested that hyperthermia can transiently enhance the delivery to the 
heated tumor site and that the use of heat shock targeting increases the interactions with 
cellular receptors resulting in greater uptake and retention within the cells [123].  
The effects of hyperthermia were visualized by MRI to examine the delivery and 
tumor distribution of untargeted HPMA copolymers labeled with gadolinium (Gd) as an 
MR contrast agent [124]. Using the same in vivo animal model, hyperthermia was applied 
whole tumor tissue including the tumor core [124]. This indicates that PPTT has the ability 










Figure 2.5: A) PPTT heating control for hyperthermia and enhanced accumulation of 
Evans blue dye (EBD) at 5 h post treatment compared to laser control. B) Plasmonic 
photothermal therapy (PPTT) temperature control, induction of heat shock proteins in 
vivo, polymer accumulation profile, and area under the curve (AUC) of the different 
polymer +/- hyperthermia groups. C) Enhanced Gd-labeled polymer accumulation over 
time as visualized by MRI. D) Enhanced efficacy of combination therapy. Results 
indicate that gold nanorod (GNR) mediated PPTT is able to selectively heat tumors while 
increasing the delivery and penetration of nanomedicines and ultimately improving 
treatment in combination therapy. These data were used with permission [122-125]. 
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period, after PPTT hyperthermia and simultaneous injection of Gd-labeled copolymers, the 
polymers accumulated to a greater extent within the heat treated tumors (Figure 2.5C) 
[124]. Furthermore, the accumulation of the copolymers was improved throughout the to 
partially overcome the high interstitial pressures within the tumor to improve spatial 
distribution in regions of the tumor that are difficult to penetrate. This can potentially be 
explained by the importance of nanocarrier size on interstitial diffusion and the use of 
hyperthermia to enhance convective and diffusive transport [124]. 
The improved accumulation, retention, and penetration of HPMA copolymers was 
correlated with enhanced efficacy showing that targeted polymer-drug conjugates 
improved tumor size reduction as compared to control groups without hyperthermia or HSP 
targeting (Figure 2.5D) [125]. In this study, synergistic effects of different copolymer-drug 
conjugates were examined with hyperthermia showing that the targeted HPMA copolymer-
docetaxel conjugates had the largest synergistic effect. It is interesting to note that in vivo 
hyperthermia alone also contributed to a reduction in tumor growth in the control group. 
However, this is expected as we have discussed hyperthermia alone influences cellular 
processes. Along with improving the effectiveness of chemotherapy, this strategy was used 
to show the added benefits for improved efficacy of combination treatment using 
radiotherapy [126].  
Another study focused on evaluating the use of GNR-mediated PPTT to increase 
delivery of somewhat larger dextran nanoparticles into the tumor [127]. This study used 
larger particles of dextran (54 nm in diameter) [127] as compared to the HPMA copolymers 
(~6 nm hydrodynamic radius) [123]. Nonetheless, this strategy for enhancing delivery has 
shown to be useful by applying heat selectively to the tumor site and improving transport 
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of nanomedicines. Finally, hyperthermia effects of GNP mediated PPTT were shown to 
produce small disruptions in the cell membrane providing enhanced uptake of drug 
molecules [128]. This enhancement of intracellular delivery was also observed using 
FeCo/graphitic carbon shell (FeCo/GC) nanocrystals (∼4-5 nm) [129]. It was demonstrated 
that enhanced intracellular drug delivery was achieved when FeCo/GC conjugated with 
doxorubicin (DOX) was exposed to 20 min of NIR laser irradiation to induce hyperthermia 
[129]. The ultimate result was a significant increase in toxicity toward breast cancer cells 
due to the PPTT heat treatment leading to an approximate two-fold enhancement of cancer 
cell uptake of the FeCo/GC-DOX complexes as well as synergistic effects of heat and DOX 
[129]. 
HIFU hyperthermia has also been shown to improve transport across the blood–
brain and tumor barriers [130]. HIFU-induced hyperthermia was able to increase delivery 
and therapeutic efficacy of polyethylene glycol-coated (PEGylated) liposomal DOX to 
brain metastasis of breast cancer [130]. Murine breast cancer 4T1 cells were injected into 
BALB/c mice striatum tissues and used as a brain metastasis model. The mice were injected 
IV with the liposomal formulation and treated with or without 10 min of transcranial HIFU 
hyperthermia [130]. This HIFU hyperthermia was able to significantly enhance the 
delivery of liposomal DOX into brain tumors and effectively inhibit tumor growth with a 
single combination treatment as compared to controls. Again, this further demonstrates that 
the application of hyperthermia after nanomedicine injection is an effective approach to 
enhance delivery and improve the treatment of cancers [130]. 
Hyperthermia effects on the tumor tissues (increased blood flow and vascular 
permeability) are largely responsible for enhanced delivery of nanomedicines. 
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Nonetheless, this can be additionally improved upon with stimuli-responsive systems. 
 
2.5.2 Thermoresponsive triggered release systems 
For hyperthermia triggered drug delivery, a majority of current research uses 
triggered temperature-sensitive delivery systems for targeted release. Much of these 
applications have been developed to target or preferentially accumulate at the tumor site 
and then selectively release their entire payload in the presence of heat or hyperthermia. 
Others have had additional success with intravascular triggered release during 
simultaneous delivery of a nanoparticle injection and localized hyperthermia. 
 
2.5.2.1 Inorganic systems 
Similar to previous PPTT methods discussed in drug delivery, GNCs have been 
used to induce hyperthermia through PPTT and create a novel drug delivery system when 
heat triggers the release of preloaded drugs from the cages’ hollow interior. GNCs were 
synthesized to absorb NIR laser light, loaded with a PEGylated alizarin dye, and coated 
with thermoresponsive poly(N-isopropyl acrylamide)-co-poly(acrylamide) (pNIPAAm-
co-pAAm) copolymers as proof of concept [81]. When irradiated with NIR laser light, most 
of the dye molecules were released within 16 min [81]. Furthermore, the GNCs were 
loaded with doxorubicin (DOX) and showed the same triggered release in the presence of 
laser irradiation in vitro for eliminating breast cancer cells. As the irradiation time 
increased, more cancer cells were killed as more DOX was released. In comparison, laser 
alone had no effect on cell death and laser with GNCs exhibited slight cell death due to 
photothermal effects [81]. 
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MNPs have also been used to form thermoresponsive systems where the particles 
were coated with temperature-sensitive polymers and encapsulated drugs forming a 
hyperthermia-based drug delivery system. These systems have been developed and 
recently dubbed as magnetothermally triggered drug delivery systems, where MFH triggers 
thermally activated materials [131]. By combining IONPs with lower critical solution 
temperature (LCST) polymers, an AC magnetic field can be used to initiate localized 
heating and trigger a phase change in the polymer coating to release drugs [131]. One such 
study has used an A-B-A triblock copolymer coating of A) PEG and B) poly(propylene 
succinate) (PPSu) [132]. This copolymer coating was shown to be biocompatible, 
biodegradable, and thermosensitive for the release of encapsulated paclitaxel when 
exposed to an AC magnetic field [132]. When the temperature was raised from 37 to 42°C, 
the polymer coating became softer as the crystalline structure was destroyed and became 
an amorphous melt structure. The loaded drug molecules were then released at a faster rate 
through the amorphous matrix as diffusion became easier through the flexible amorphous 
polymer chains [132]. Magneto-thermally triggered systems have also been used by coated 
IONPs with N-isopropyl acrylamide as a thermosensitive monomer and N,N-methylene 
bisacrylamide as the crosslinker. These particles were shown to generate sufficient heat for 
hyperthermia application and controlled release experiments demonstrated excellent drug 
loading and temperature-triggered release of 5-fluorouracil [133]. 
 
2.5.2.2 Organic systems 
Release from liposomal drug delivery systems in the absence of external stimuli 
can be very slow [134]. The entrapped drugs need to be released from the liposomes in 
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order to reach tumor cells for a therapeutic effect. Thus, to create a system that can protect 
the drug from rapid excretion and have a targeted release, thermosensitive liposomes 
(TSLs) have been developed in conjunction with local hyperthermia [135]. Many strategies 
have been employed to create a rapid release and much of this research has focused around 
liposomal nanomedicines that have temperature sensitive groups (i.e., specific lipids, 
polymers, or other modifiers) incorporated within the liposomal formulation to trigger the 
release of their payload in the presence of heat above a certain threshold [136-140]. Yatvin 
et al. has pioneered this area, developing TSLs composed of phospholipids having 
transition temperatures slightly above normal physiological temperature to rapidly release 
pharmaceuticals under heating conditions [135]. For applications in oncology, TSLs can 
be used in combination with localized hyperthermia to create a new effective drug delivery 
system. In vivo, the liposomal formulation is injected just prior to or during hyperthermia 
treatment and immediate release of their contents is initiated upon arrival to the heated 
tumor area. Local hyperthermia causes the lipid structures in the liposomes to ‘‘melt’’, and 
the liposomes flowing through the vascular bed of a heat treated area rapidly release the 
entrapped drug into the surrounding tissues [135].  
The use of TSLs with hyperthermia has been studied extensively with heating 
modalities such as MFH and HIFU. MNPs have been used successfully in cancer therapy 
for MFH as described earlier. In combination with TSLs, magnetic formulations have been 
developed for drug targeting and eventual triggered release by MFH [141, 142]. These 
liposomes have been additionally directed to the tumor site by a permanent gradient 
magnetic field [143]. Once at the tumor site, magnetic liposomes are then triggered to 
create heating and quickly release the therapeutic payload under an AC magnetic field 
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[141]. This fast release is due to the particles being embedded within the lipid bilayer and 
produces direct lipid phase transition [142]. Taken together, these multifunctional targeted 
magnetic TSLs enable improved tumor cell killing in comparison to nonmagnetic targeted 
liposomes [141, 144].  
Many additional strategies have been used to improve the combination of TSLs 
with hyperthermia. On the chemistry and synthesis side, this includes creating liposomes 
that have optimized heat sensitivity. TSLs are comprised of lipids and some combination 
of cholesterol and/or PEG-conjugated lipid for prolonged blood circulation [53]. Release 
properties of these TSLs have been extensively studied and lead to an optimized molar 
percentage of lysolipids in dipalmitoylphosphatidylcholine (DPPC) bilayers to form 
stabilized defects in the membrane during the phase transition and enhanced release within 
tens of seconds [53]. Alternatives to lysolipids, which may desorb from liposomal shells 
and thus compromise the stability and/or thermosensitivity of the liposome, have also been 
studied such as the use of synthetic temperature-sensitive polymers to improve the 
responsiveness [145]. Liposomes modified with thermosensitive polymers (TSPs), for 
example, poly(N-isopropyl acrylamide) (NIPAAm), aggregate at temperatures above this 
LCST [146]. Anchored to lipid membranes via hydrophobic interactions, they dehydrate 
and collapse at the LCST, disrupting the TSL membrane inducing drug release. 
Additionally, the LCST of these TSPs can be tuned through copolymerization with a 
variety of monomers, which also affects the extent of drug release [53].  
Strategies have focused on making these liposomes more sensitive to hyperthermia 
while others have taken the approach of additionally targeting the system towards receptors 
or ligands. One such method was developed encapsulating drugs within targeted cationic 
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TSLs [147]. The cationic charged lipids improve specificity to tumor vasculature and tumor 
cells along with a thermosensitive liposomal bilayer for heat-triggered drug release [147]. 
The cationic TSLs selectively target angiogenic endothelial cells and tumor cells based on 
electrostatic interactions between their cationic surface and overexpressed anionic 
molecules on angiogenic endothelial and tumor cell membranes [148, 149]. Combining the 
targeting functionality and internalization properties of cationic liposomes with a heat-
triggered release function can ensure controlled release of drug contents at the tumor site 
while also improving the permeability of these liposomes throughout the tumor tissue 
[147]. Several investigators have studied TSLs that were modified with targeting ligands 
such as peptides, aptamers, and folate [150]. These targeting ligands exhibit binding 
affinity for cancer cells and triggered drug release when exposed to hyperthermia [151, 
152].  
The method of hyperthermia which has received the most attention in combination 
with nanomedicines such as TSLs has been HIFU. This method has several advantages 
mentioned previously. Other heating modalities for triggering drug release from these 
TSLs have generally suffered from limited penetration depth, invasiveness, insufficient 
spatial and temporal control of heating, and insufficient and invasive monitoring of heating. 
For localized heat-triggered drug release from TSLs, several groups have demonstrated the 
potential of HIFU-TSL systems [48, 153-158]. In particular, Dromi et al. demonstrated in 
a preclinical model that TSL combined with hyperthermia from HIFU enhances drug 
deposition at the tumor and delays tumor growth relative to treatment without HIFU [153].  
Combinations of HIFU hyperthermia can be used to enhance the delivery of TSLs 
and show increased levels of extravasation of liposomes with increasing temperatures from 
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39 to 42°C applied for 60 min [159]. It was also demonstrated that the increased vascular 
permeability in this tumor model lasted up to 4 h after treatment. In more recent work with 
the combination of TSLs and MRgHIFU, Ranjan et al. were able to demonstrate enhanced 
drug accumulation within the tumor site [160]. Manzoor et al. have also shown that the use 
of TSLs in combination with hyperthermia is able to increase the amount of drug 
accumulation in heated tumors versus nonheated and nonencapsulated drug controls [161]. 
The combination of TSL encapsulated administration of DOX and hyperthermia leads to 
the intravascular release of drug and higher amounts of tumor accumulation than with 
either alone [161]. The absence of heat leaves the drug within the liposomes and confined 
within the vessels whereas free drug and heat only create a transient increase in drug 
accumulation for 1-5 min [161]. Interestingly, both groups have shown that tumors heated 
with TSL and hyperthermia showed a greater amount of drug was able to penetrate to the 
tumor core [160, 161]. This effect was additionally observed using PPTT and HPMA 
copolymers and is again important to note since delivery of drugs to this region has been 
difficult. This phenomenon is likely due to the hyperthermia effects reducing the interstitial 
pressure while improving tumor perfusion but may also be attributed to vibrational forces 
from ultrasound creating better penetration [160]. Nevertheless, this combination therapy 
was shown to enhance the delivery of therapeutics by Rajan et al. resulting in a 3.5- and 
7.6-fold more tumor accumulation in TSL and DOX control groups, respectively, and 
Manzoor et al. were able to show a nine-fold increase in DOX accumulation over 20 min 
as compared to control groups of free drug [160, 161].  
The sequence at which HIFU-induced hyperthermia is applied has been studied by 
a few different groups. Grüll et al. applied hyperthermia either directly after or 24 h after 
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injection with the drug formulation [157]. HIFU hyperthermia directly after the injection 
of TSLs resulted in the greatest increase in drug concentration in the tumor in their studies. 
HIFU hyperthermia performed 24 h after the injection of the TSLs showed no further 
increase in drug accumulation likely due to clearance of the TSLs from the blood within 
that time frame. As expected, the increased drug concentrations within the tumor lead to 
reductions in tumor growth compared to controls [157]. This type of study was also 
performed by Li et al. but in the opposite sequence meaning HIFU hyperthermia was 
applied first and then TSLs were injected [121]. Hyperthermia induced hyperpermeability 
within the tumor vasculature which remained for approximately 8 h and was used to 
enhance the delivery of TSLs [162]. After maximal accumulation and penetration, a second 
dose of hyperthermia was used to trigger release from the TSLs. This two-step approach 
lead to greater accumulation as compared to if there was no first step hyperthermia [121]. 
Therefore, taken altogether, it is likely best to start hyperthermia before injection of TSLs 
in order to predispose the tumor tissue for enhanced accumulation by vascular mechanisms 
and continue heating for some time after injection for complete intravascular release of the 
therapeutic payload of all TSLs in the heated area during peak plasma concentration of the 
liposomal drug. Finally, mathematical models have been used to compare the 
administration of free DOX, liposomal encapsulation (stealth and TSL) and the optimal 
regimen for inducing hyperthermia for triggered release, be it intra- or extra-vascular [163]. 
In these studies, the amounts of intracellular drug concentrations were compared showing 
that intravascular release had the highest accumulation with a concentration of 100.6 µg/g 
versus 15.9 µg/g for extravascular release, 3.4 µg/g for free DOX, and 0.4 µg/g for stealth 
liposomal DOX [163]. As liposomal formulations of DOX are known to reduce cardiac 
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toxicity [164], the accumulation of the drug in cardiac tissues was also examined. The ratio 
of drug exposure between tumor and cardiac tissue for each DOX formulation was 
determined that extravascular released TSLs were best followed by fast-release 
intravascular TSLs, slow-release intravascular TSLs, stealth liposomal DOX, and free 
DOX in that order [163].  
In summary, several groups have shown that this combination results in a greater 
amount of drug accumulation at the tumor in response to heating and triggered release, 
reducing the required drug dose and more importantly enhancing the efficacy of treatment 
leading to better tumor reduction having the potential to effectively eliminate cancers. As 
a source of hyperthermia to trigger drug release from TSLs, several have employed HIFU 
as it is more advantageous in terms of its noninvasiveness as compared with other methods 
such as microwave, radio frequency, and NIR laser heating that require an interstitial 
needle or insertion of an antenna or fiber optic probe.  
It is noteworthy for possible translation of this method that the lysolipid TSL 
formulation developed by Needham and Dewhirst’s groups at Duke University has 
undergone further pharmaceutical development by the biopharmaceutical company 
Celsion, marketed as ThermoDox®. This system has previously gone through Phase I/II 
clinical trials for the treatment of hepatocellular carcinoma and has now reached Phase III 
clinical trials in combination with radiofrequency ablation (RFA). In Phase I trials patients 
were given a 30-min infusion, 15 min prior to RFA. The study was able to determine the 
peak plasma concentration to be at 30 min (coincident with the end of infusion), an initial 
half-life of approximately 1 h, and maximum tolerated dose (MTD) of 50/mg/m2 [165]. A 
statistically significant difference in the time to treatment failure was observed between the 
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patients receiving at least the MTD and patients receiving less than the MTD (374 vs. 80 
days, respectively). The study concluded that the combination of RFA and ThermoDox® 
was safe and likely more efficacious than RFA alone. These results formed the rationale 
for a multinational phase III trial for the treatment of hepatocellular carcinoma. The latest 
results have shown that as of January 15, 2015, the latest quarterly overall survival (OS) 
analysis at the time of this writing, in a large subgroup of patients with single HCC lesions 
(n=285, 41% of the study patients), the combination of ThermoDox® and optimized RFA 
provided a 59% improvement in OS compared to optimized RFA alone [166]. A phase I 
trial has been completed and a phase II trial has been initiated for the treatment of recurrent 
chest wall disease in breast cancer patients with the combination of ThermoDox® and 
hyperthermia [167]. The interim results have been posted on Celsion’s website and based 
on the data available to date (4/2015), 67% of patients experienced a clinical benefit of 
their highly refractory disease with a local response rate of 58% observed in the 12 
evaluable patients, notably 5 complete responses (CR), 2 partial responses (PR) and 1 
patient with stable disease (SD) [168]. Because of the broad range of doxorubicin antitumor 
efficacy, ThermoDox® has the potential to be used to treat multiple other cancer types. 
Celsion is also interested in initiating clinical trials to assess the use of HIFU in 
combination with ThermoDox® for the treatment of metastatic bone cancer. Additionally, 
Celsion is looking into the treatment of pancreatic cancer with ThermoDox® [169].  
Similarly, thermosensitive micelles have been studied with hyperthermia for 
enhanced delivery to solid tumors. Over the past decade, considerable efforts have been 
devoted to design and prepare NIPAAm-based thermosensitive polymeric micelles as 
delivery vehicles for controlled drug release [170]. Biodegradability can also be 
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incorporated using poly(D,L-lactide), poly(ε-caprolactone), or poly(D,L-lactide-co-ε-
caprolactone) as the hydrophobic block of the amphiphilic block copolymers [171]. These 
micelles exhibit rapid and thermoresponsive drug release for combination with thermal 
therapy [171]. 
In vitro release behavior showed a dramatic thermoresponsive fast/slow switching 
behavior according to the temperature responsive structural changes of a micellar structure 
[172]. In vivo with radiofrequency heating, smaller thermosensitive micelles resulted in 
superior tumor penetration and more effective local molecular modulation whereas larger 
long-circulating liposomal carriers resulted in greater intratumoral drug accumulation over 
time and reduced tumor growth. Accordingly, different carriers provide specific 
advantages, which should be considered when formulating optimal combination therapies 
[173]. 
It has been shown that thermally responsive elastin-like polymers (ELPs) can be 
used as triggered delivery release system to enhance targeted delivery to solid tumors. 
ELPs are genetically engineered, thermally responsive polypeptides that can be guided to 
accumulate in solid tumors treated with mild hyperthermia [174]. Thermoresponsive ELPs 
accumulated in solid tumors at a significantly greater level than in unheated tumors or with 
a thermally insensitive ELP in heated tumors [174]. It was additionally shown that the 
thermos-cycling (repeated heating with hyperthermia) of the tumor region would form 
micron-sized aggregates from circulating ELPs that would adhere to the tumor vasculature 
thus enhancing the delivery to the tumor site [158]. This effect was shown to be repeatable 
as the formation of adherent microparticles of ELP were produced in the heated tumor 
vasculature in each thermal cycle [158]. This leads to a highly specific thermally targeted 
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system to improve delivery to heated tumors as the thermosensitive ELPs will only 
aggregate in the heated tumor.  
 
2.6 Conclusion 
Much work has been accomplished to create a combination therapy for 
hyperthermia with nanomedicines. Several types of nanoparticles have been developed 
including those with thermosensitivity as well as different methods for inducing localized 
heating with solid tumors. Clinical challenges of hyperthermia methods include improved 
selectivity to the tumor site as well as reducing invasiveness. The use of either GNPs or 
MNPs for PPTT or MFH respectively requires injection of particles systemically or directly 
into the tumor site. The accumulation in healthy filtration organs, when delivered 
systemically, causes concern for long-term exposures and largely prevents further 
development in the clinic. Additionally, if the particles are injected directly into the tumor, 
this requires that the tumor be superficial (i.e., head and neck cancer) or otherwise easily 
accessible. EM radiation of microwaves and radiowaves has been used in clinical 
applications, but the use of minimally invasive needles or antennas can cause damage to 
surrounding tissues and may require several probes to effectively heat the entire tumor.  
Of the methods that were described above, the heating method that has shown the 
most promise for localized hyperthermia of solid tumors has been HIFU. This method is 
noninvasive and can be used to treat tumors with the exception of those in air-filled cavities 
such as the lungs. It may be possible though that PPTT or MFH can be used in those 
instances. Nonetheless, HIFU has undergone recent advances for selectively heating 
tumors with MRI guidance. For hyperthermia treatment, however, there is a need for a 
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computational feedback system with MR thermometry that can determine the thermal 
dosing and other parameters such as raster pattern and speed to reproducibly heat different 
tumor sizes and types with hyperthermia. Robust temperature controlling, including 
algorithms for motion compensation during the procedure, are essential for such a system. 
Uniform heating of specific temperatures within the tumor tissue and reproducibility from 
tumor to tumor is very important for improved drug delivery. Improved modeling software 
and computer algorithms are required to create this system. The clinical relevance of HIFU 
provides hope that there will be a clinically approved hyperthermia system for combination 
therapy with nanomedicines. 
Novel nanoparticle formulations have been created for combination with 
hyperthermia, through heat shock targeting and temperature sensitive delivery systems. 
Additionally, other methods have been developed to deliver both heat from PPTT or MFH 
with triggered drug release. It is important to note that several of these nanoparticles are 
going through or have been through clinical trials such as Thermodox and other carriers 
including HPMA copolymers. Several nanoparticle types have been studied in their 
combination with hyperthermia, both thermo- and nonresponsive. These systems in 
combination with hyperthermia have been shown to greatly enhance tumor localization and 
accumulation as well as efficacy. Despite the challenges described above, substantial 
progress has been made in using hyperthermia for enhancing the delivery of nanomedicines 
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EFFECTS OF HEATING TEMPERATURE AND DURATION BY GOLD 
NANOROD-MEDIATED PLASMONIC PHOTOTHERMAL THERAPY  
ON COPOLYMER ACCUMULATION IN TUMOR TISSUE 
 
3.1 Introduction 
Increased delivery and accumulation of chemotherapeutics to solid tumors has 
received much attention in the past decades. Improved delivery of chemotherapeutics to 
solid tumors can enhance therapy and reduce toxicity. Delivery of conventional drugs lacks 
significant accumulation and selectivity to the tumor site leading to insufficient elimination 
of cancer cells as well as side effects that can threaten the life of the patient, restricting 
further dosing. Poor drug accumulation and penetration within the tumor tissue can be 
attributed to several factors resulting from tumor anatomy that makes delivery difficult. 
These include physiological barriers as a result of growth induced solid stresses, dense 
interstitial structure, elevated interstitial pressures, and abnormal blood vessel networks 
within many tumor types [1]. The extent to which these characteristics are expressed is also 
variable within and between tumor types [2]. Additionally, poor water solubility and short 
circulation half-lives of many chemotherapeutics limit their bioavailability. Recent 
Reprinted in part with permission of ACS. N. Frazier, R. Robinson, A. Ray, H. 
Ghandehari. Effects of heating temperature and duration by gold nanorod-mediated 
plasmonic photothermal therapy on copolymer accumulation in tumor tissue. Molecular 




developments in nanomedicine have focused on combating these problems by increasing 
the amount of drug delivered to the target site and reducing harmful side effects from 
accumulation in healthy vital organs such as the liver, spleen, and kidneys.  
One strategy for targeted drug delivery has been to attach different therapeutic 
agents to the side chains of water-soluble polymers. Polymer-drug conjugates or polymer 
therapeutics have been used in a variety of applications to aid delivery of hydrophobic 
drugs to cancers [3-8]. N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers, 
specifically, have been utilized often due to their hydrophilicity, biocompatibility, and 
multifunctionality [9, 10]. Conjugation of hydrophobic anticancer agents to these 
copolymers improves the water solubility of hydrophobic drugs, prolongs blood circulation 
times (sizes above 45 kDa to avoid renal clearance) [11], allows for passive and active 
targeting strategies, and alters the mode of cellular internalization from passive diffusion 
or transporter mediated internalization to endocytosis, overcoming multidrug resistance 
from drug efflux pumps [9]. Several different drugs have been conjugated to HPMA 
copolymers including doxorubicin [12, 13], paclitaxel [14], docetaxel [14, 15], cisplatin 
[16], aminohexylgeldanamycin [17], and camptothecin [18] as well as radiotherapeutics 
[19, 20] and gene therapies [21]. Although improvements in drug delivery have occurred 
with polymer-drug conjugation, the potential for clinical translation is still hampered by 
the relatively low accumulation and tumor mass penetration in solid tumors [1]. 
Improvements in localization, penetration, and efficacy can advance the clinical 
applicability of HPMA copolymer-drug conjugates.  
Previously, it was shown that gold nanorod (GNR) mediated plasmonic 
photothermal therapy (PPTT) is capable of increasing the overall accumulation of albumin 
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and HPMA copolymer conjugates [22, 23], tumor penetration [24], and improve the 
efficacy of prostate cancer treatment [15, 20]. GNR mediated PPTT is a method of heating 
tumors selectively through absorption of near infrared (NIR) laser light. In these previous 
studies, tumors were treated with mild hyperthermia (43°C for 10 min) which was first 
shown to maintain the temperature within the tumor at 42-43°C and enhance 
macromolecular delivery through increased accumulation of Evans blue dye (EBD) at 5 h 
post treatment [22]. PPTT was additionally shown to improve delivery of untargeted and 
heat shock targeted HPMA copolymers [23]. In these studies, it was shown that untargeted 
polymer accumulation after PPTT led to a transient increase in accumulation peaking at 4 
h and returning to baseline at 8 h post treatment [23]. With the incorporation of heat shock 
targeting, the enhanced accumulation was retained over longer periods of time [23]. The 
enhanced accumulation was finally visualized by MRI. These experiments showed that 
PPTT could also increase the penetration of HPMA copolymers within the tumor tissue 
[24].  
The enhanced accumulation and penetration were finally examined with chemo- 
and radio-therapeutic copolymer conjugates. Efficacies of heat shock targeted and 
untargeted HPMA copolymer-docetaxel conjugates were shown to be significantly 
improved over free drug alone with significant improvements in synergy as well [15]. 
Additionally, 90Yttrium was conjugated to HPMA copolymers and used in conjunction 
with PPTT [20]. The efficacy of these conjugates was also greatly improved as 
radiotherapy is known to have improved effects in combination with hyperthermia.  
In each of these experiments, the same heat treatment was used to improve delivery 
and enhance treatment in preclinical prostate cancer models. However, limited information 
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is available on the role of varying heating parameters (temperature and duration) of PPTT 
and the effects on HPMA copolymer accumulation, retention, and consequently efficacy. 
Work described in this chapter aims to investigate how altering heating parameters of PPTT 
can change polymer accumulation profiles. In this study, different heating temperatures 
and durations of heat were used and changes in polymer accumulation within the heated 
tumors were observed. It was observed that altering the heating duration between 10 or 30 
min and temperatures of 40, 43, 46, and 49°C had a significant effect on polymer 
accumulation. As these temperatures and times vary with different combinations of each, 
it is then valuable to consider these treatments as thermal doses. Using the equation 
developed by Sapareto and Dewey the different treatments can be compared on the same 
scale [25].  
 
3.2 Materials and methods 
3.2.1 Materials 
 Gold(III) chloride solution, hexadecyltrimethylammonium bromide (CTAB), silver 
nitrate, ascorbic acid, sodium borohydride, methacryloyl chloride, amino-2-propanol, 
tyrosinamide, 2-cyano-2-propyl dodecyl trithiocarbonate, and Iodogen (1,3,4,6-
Tetrachloro-3α,6α-diphenylglycouril), were all purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Poly(ethylene glycol) (mPEG-SH, MW=5 kDa) was purchased from Creative 
PEG works (Winston-Salem, NC, USA). Spectra/Por 6 dialysis tubing, (10K MWCO, 
45mm flat width, 33-foot length) was purchased from Spectrum Laboratories (Rancho 
Dominguez, CA, USA). 2,2'-Azobis[2-(2-imidazolin-2-yl)propane] dihydrochloride (VA-
044) was purchased from Wako Pure Chemical Industries (Richmond, VA, USA). 
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125Iodine radionuclide as sodium iodide was purchased from American Radiolabel 
Chemicals (St. Louis, MO, USA).  
 
3.2.2 Synthesis and characterization of HPMA copolymers 
HPMA [26] and N-methacryloyl-tyrosinamide (MA-Tyr) [27] comonomers were 
synthesized as described previously. Copolymerization of these two monomers was 
performed by reversible addition-fragmentation chain transfer (RAFT) polymerization 
using 2-cyano-2-propyl dodecyl trithiocarbonate as the chain transfer agent (CTA) and 
VA-044 as the initiator in methanol at 50°C for 24 h. The product was then precipitated 
and washed with diethyl ether followed by dialysis against deionized water to remove 
unreacted monomers, CTA, and initiator. The copolymers were lyophilized to obtain the 
final product. Weight average molecular weight (Mw), number average molecular weight 
(Mn), and polydispersity index (Mw/Mn) were estimated by size-exclusion 
chromatography (SEC). 
MA-Tyr comonomer was included in copolymerization for the ability to attach the 
radiolabel 125Iodine by the Iodogen method with slight modification [28]. The synthesized 
copolymer (2 mg) and 0.5 mCi Na-125I were dissolved in 0.5M NaH2PO4 at pH 7.0 and 
incubated at room temperature in Iodogen tubes for 10 min. Free radiolabel was removed 
by dialysis against 0.9% saline and verified by SEC for radiolabel attachment and purity 
of the polymer conjugate using a disposable size exclusion PD10 column. Radiolabeled 
copolymers were used to track accumulation within tumor tissue and quantify enhancement 




3.2.3 Synthesis and characterization of gold nanorods 
Poly(ethylene glycol) (PEG) coated GNRs were synthesized according to 
procedures described previously by seed-mediated growth methods [29]. This method has 
been optimized for yielding GNRs with an aspect ratio such that the corresponding surface 
plasmon resonance (SPR) absorbance peak lies between 800 and 810 nm. To remove large 
amounts of CTAB used during the synthesis, the particles were washed three times with 
deionized water by centrifugation. Subsequently, the GNRs were PEGylated by addition 
of methoxy-PEG-thiol to the particle suspension with a final PEG concentration of 100 μM 
and stirred for 1 h. The suspension was dialyzed against deionized water using a 10 K 
MWCO dialysis bag to remove excess PEG and remaining CTAB and finally concentrated 
by centrifugation to 120 optical density (OD) and sterile filtered for later use in animal 
experiments. Characterization was performed by transmission electron microscopy (TEM) 
(FEI Tecnai T12 microscope, University of Utah Core Research Facilities, Salt Lake City, 
UT, USA) to determine the size and shape of the particles and ultraviolet (UV) 
spectrophotometry to characterize the light absorbance profile of the GNRs.  
 
3.2.4 Tumor model 
In vivo experiments were carried out with CD1 mice containing two S-180 
subcutaneous sarcoma tumor xenografts, one on each flank. Inoculations were performed 
by injecting 200 μL containing 10x106 cells subcutaneously and allowing tumors to grow 
for 7-10 days to reach 7 mm in diameter. Once the tumors reached their desired size, they 




3.2.5 Polymer accumulation 
Once the tumors were the appropriate size, 200 µL of PEGylated GNRs in 0.9% 
saline were injected intravenously via tail vein at an OD ≈ 120 with a total mass of GNRs 
≈ 725 µg. The particles were allowed to circulate for 48 h before PPTT. After the particles 
had accumulated in the tumor tissue, mice were anesthetized (2% isoflurane) and tumor 
regions were shaved and swabbed with 50% propylene glycol to enhance laser penetration 
depth [30]. Tumors on the right flank only were then radiated using an 808nm fiber-coupled 
laser diode (Oclaro Inc., San Jose, CA) with collimating lens with a spot size = 15 mm in 
diameter (Thorlabs, Newton, NJ) able to cover the entire tumor. The intratumoral 
temperature was monitored using a 33 gauge needle thermocouple (Omega, Stamford, CT) 
and tumor temperature was maintained between +/- 0.5°C. For these experiments, the laser 
power ranged from 1.0 to 1.6 W/cm2 depending on the desired temperature. In order to 
maintain the heating temperature at the predetermined heat schedule, the laser power was 
adjusted slightly in real time. The right tumors were heat treated with PPTT with a 
predetermined heat schedule (10 or 30 min at either 40, 43, 46, or 49°C). The left tumors 
were untreated to serve as an internal control accounting for possible variances in injected 
dose of radiolabeled HPMA copolymers from animal to animal and as a reference for 
calculating thermal enhancement ratio (ratio of accumulation in heated tumor/unheated 
tumor). Immediately before treatment, 125I radiolabeled HPMA copolymers were injected 
intravenously, 200 µL with 7.5 mg/ml dissolved in 0.9% saline for a dose of 50 mg/kg and 
120,000 counts per minute (CPM). The working solution was prepared by first dissolving 
unlabeled polymers at the appropriate concentration and then adding a small amount of 
radiolabeled polymers to achieve a radioactive dose of 120,000 CPM. At 2, 4, 6, and 8 h 
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post treatment the animals were euthanized by CO2 inhalation, tumors were removed, 
weighed, and gamma counted. Radioactive polymer accumulation for all combinations of 
temperatures and durations were measured for radioactivity levels at 4 h while only select 
groups (tumors treated with 43, 46, or 49°C for 10 min and 46°C for 30 min) were analyzed 
over an 8 h period. The radioactivity in each tumor correlates to polymer accumulation 
over time with the ratio of right to left tumor giving the thermal enhancement ratio (TER).  
 
3.2.6 Tumor histology 
Histological analysis was performed to observe damage to tumor vasculature after 
PPTT groups treated with 43, 46, or 49°C for 10 min and 46°C for 30 min. The same 
procedure was followed for GNR injections and PPTT in Section 2.5 except no injection 
of radiolabeled copolymers was performed. Ten hours post treatment animals were 
sacrificed, tumors were removed and fixed in neutral buffered formalin, paraffin-
embedded, sectioned, stained with hematoxylin and eosin (H&E), and imaged by light 
microscopy. Tumor samples were analyzed for signs of vascular damage. Untreated control 
tumors were also included. 
 
3.2.7 Statistics 
Statistical analyses were performed in GraphPad Prism. Comparisons between two 
groups (left vs. right tumors) were performed by one-way ANOVA for each group. P-
values less than 0.05 were considered statistically significant (* P ≤ 0.05, ** P ≤ 0.01, *** 





3.3.1 HPMA copolymer synthesis and characterization 
 The HPMA copolymers were synthesized by RAFT copolymerization to be 
approximately 60-80 kDa to have a size slightly above the renal threshold and take 
advantage of the EPR effect as well as being consistent with the size of other polymers 
used in accumulation studies [23, 24] (Table 3.1). Copolymers included MA-Tyr 
comonomer for eventual radiolabeling with 125I. The attachment of 125I was confirmed by 
determining the elution volumes of free and conjugated 125I. 
 
3.3.2 GNR synthesis and characterization 
The GNRs were synthesized with an SPR peak at 810 nm (corresponding to a size 
of 62 × 17 +/- 7 × 2 nm with an aspect ratio equal to 3.6, Figure 3.1) as light at this 
wavelength is capable of penetrating tissue several centimeters [31]. These GNRs are found 
to be stable in a wide variety of buffers including saline due to steric protection from 
aggregation. 
 
3.3.3 HPMA copolymer accumulation 4 h after treatment  
with PPTT 
In this experiment, animals (n=5) were administered with GNRs 48 h prior in order 
to localize within the tumor tissue and allow for heat treatment with PPTT. The heating 
parameters were altered between a total of eight combinations using four different 
temperatures (40, 43, 46, or 49°C) and two different heating durations (10 or 30 min). The 

















Table 3.1:  HPMA copolymer characteristics 
Sample Apparent MW (Mw) Polydispersity Index (PDI)
HPMA-
125
I 78.0 KDa 1.21
Figure 3.1: Characterization of gold nanorods by transmission electron 




h post treatment (Figure 3.2). It was observed that for both 40°C groups there is minimal 
enhancement of polymer accumulation at 4 h post treatment (TER ≈ 1.2). For both 43°C 
treatment groups, there is a larger peak of accumulation at 4 h (TER ≈ 1.6) which is 
consistent with previous experiments [22-24]. There is a slight decrease in average 
accumulation for the 43°C/30 min group but not statistically significant compared to the 
43°C/10 min group. The 46°C group does not have much accumulation when treated for 
10 min but increases when applied for 30 min (TER ≈ 1.2 vs 1.6). Both 49°C groups have 
increased accumulation (TER ≈ 1.5). Polymer accumulation at 4 h had significantly 
decreased for the 46°C/10 min group but then increased again for the 46°C/30 min as well 
as for both 49°C groups. 
 
3.3.4 HPMA copolymer accumulation over 8 h with select groups 
Select groups were examined for polymer accumulation over 8 h post treatment. 
These groups included 43, 46, and 49°C for 10 min and 46°C for 30 min with the TER of 
each group shown in Figure 3.3. First, this data shows that the peak accumulation 
enhancement for 43°C occurs at 4 h. As the thermal dose is increased to 46°C for 10 min, 
the same peak in enhancement is shifted to 2 h post treatment. Similar accumulation is 
observed at 2 h for 49°C which does not return to baseline (TER > 1.2) until 8 h post 
treatment. The treatment group that observed the highest accumulation enhancement and 
retained accumulation for at least 8 h was the treatment of 46°C for 30 min.  
The area under the curve (AUC) for each of these groups was determined and 
compared (Figure 3.4). The comparison shows that there is a similar accumulation over the 











Figure 3.2: Polymer accumulation 4 h post treatment with combinations of 








































further to 46°C for 30 min, the AUC is significantly larger (≈ 7) while it is also interesting 
to note that the heat treatment with 49°C for 10 min saw the AUC drop back down to 3.  
 
3.3.5 Tumor histological analyses for observations of tumor vascular  
damage 
Tumor histology was used to examine vascular damage caused by PPTT and to help 
understand the vascular mechanisms involved with polymer accumulation. Histological 
analyses were performed in the same four groups as the previous section (3.3.4) and also 
including a nonheated control tumor. Based on the observation made from the image 
analysis of these tumor sections the damage to the tumor vasculature was observed to 
progressively increase in groups 46°C for 10 min to 49°C for 10 min with no signs of 
damage seen in the lower temperature groups (Figure 3.5). There are small signs of red 
blood cell damage and clot formation in 46°C for 10 min which continues to grow in 46°C 
for 30 min. Finally, as seen in 49°C for 10 min there are vessels present in the tissue that 
have been completely occluded with small numbers of red blood cells (RBCs) entrapped. 
It is important to note that not all vessels exhibit the same vessel damage but the extent of 
progressive vascular damage is distinct for these groups represented in the images of Figure 
3.5 such that only this extent of damage is observed in the specific treatment group. The 
top image for each group shows a section of tumor tissue with a blood vessel labeled with 
a blue arrow with the bottom image zoomed in on the labeled blood vessel to better observe 
RBC damage. In the magnified image at 100x magnification, clot formation within the 
vessel is labeled with yellow arrows and changes in RBC morphology are labeled with red 







Figure 3.5: Histology sections of untreated and treated tumors. Arrows Blue: blood 
vessels, Red: lymphatic vessels, Red: red blood cell morphology, Yellow: fibrin 





3.6 Thermal dose equivalent 
To better present this data based on the arbitrary combination of temperature and 
time, each thermal dose was converted to time (min) at 43°C for better comparison [25]. 
This was done using the equation in Figure 3.6A which was previously developed for 
comparison of heat treatments in clinical applications. Previous data of Figure 3.2 was 
converted to the thermal dose equivalent to help aid discussion. As the thermal dose (time 
at 43°C) increases from about 10 s to 10 min, the accumulation at 4 h increases. After this 
point, the accumulation begins to decrease as thermal dose increases from 10 to 80 min. 
As thermal dose continues to increase to 240 min the accumulation enhancement increases 
again. However, as the thermal dose is increased from 240 to 640 min the amount of 
polymer delivered to the tumor site is reduced. 
Next, the AUC of Figure 3.4 was additionally plotted against the thermal dose 
equivalent to each treatment group to better present the effects of altering the heating 
regimen (Figure 3.6C). As the dose increases from 10 to 80 min, the AUC does not change.  
As thermal dose further increases to 240 min, the AUC drastically rises. There is then a 
drop in AUC for the last group when the dose reaches 640 min. 
 
3.4. Discussion 
Previous studies in our lab have shown to significantly enhance the delivery of 
macromolecular polymer conjugates with PPTT at 43°C for 10 min [22-24]. This heating 




Figure 3.6: A) Equation for thermal dose equivalent for time (min) at 43°C, B) Polymer 
accumulation at 4 h of all groups plotted against thermal dose equivalent time at 43°C, C) 
Area under the curve plotted against thermal dose as a function of time at 43°C. 










and was further improved through the use of specific heat shock targeting strategies 
increasing cellular uptake and tumor tissue retention [23]. It was unknown, however, if 
altering the heating regimen would alter the accumulation profile and therefore it was of 
interest to investigate if the conjugate accumulation could be further optimized for maximal 
enhancement with the use of different heating parameters.  
In this study, the heating regimen was altered between temperatures of 40, 43, 46, 
and 49°C and with heating durations of either 10 or 30 min. It was observed that these 
changes lead to significant differences in polymer accumulation enhancement profiles with 
different groups. Finally, it was suggested that this study could advance the mechanistic 
understanding of tumor vascular events that occur in response to heat treatment ultimately 
leading to improved accumulation of polymer-drug conjugates and greater therapeutic 
efficacy.  
The temperatures for these experiments were chosen in increments of 3°C starting 
from 43°C as this was used in prior experiments [15, 20, 22-24]. It is widely considered 
that temperatures above 46°C are thermoablative [32]. Therefore, temperatures at 46°C and 
one above (49°C) were selected. Finally, one temperature lower than 43°C was selected to 
observe how longer durations could affect treatments with lower temperatures (40°C) and 
therefore the duration was extended to 30 min for all groups versus only 10 min used in 
prior experiments [15, 20, 22-24]. The polymer accumulation was initially chosen to be 
observed at 4 h post treatment as this is the time where the peak of accumulation was 
observed in previous experiments [22-24] and was also consistent with our results showing 
the peak accumulation occurs at 4 h for 43°C for 10 min. It was later realized that 4 h may 
or may not be the peak accumulation time for all other treatment groups and therefore the 
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accumulation profile was expanded at 2 h intervals to 6 and 8 h post treatment correlating 
again back to previous studies showing a return to baseline accumulation 8-12 h later [22-
24]. Lastly, an early time point was included at 2 h to have 2 h intervals over the whole 8 
h time period.  
Some previous studies have used prostate cancer animal models for examining the 
effects of PPTT on polymer accumulation [23, 24]. S-180 tumors were used here as they 
are known to exhibit the enhanced permeability and retention effect for passive 
accumulation of GNRs and ability to observe augmentation of this effect with hyperthermia 
without the need of an immune compromised mouse strain. Additionally, heat shock 
targeting would not be used in these experiments where prostate cancer cells are known to 
express these cell surface receptors. The molecular weight of the HPMA copolymers was 
also designed to be above the renal threshold for long circulation to additionally take 
advantage of the EPR effect and observe the ability for PPTT heat treatments to alter this 
phenomenon.  
Initially, the polymer accumulation for all heat treatment groups was observed at 4 
h post PPTT as it was shown that the peak accumulation of untargeted polymers occurs at 
this time in previous studies [23]. With examination of these results (Figure 3.2), the trend 
of increasing polymer accumulation for 40 and 43°C groups followed by a drop in TER for 
46°C/10 min and subsequent increase again for 46°C/30 min and 49°C groups became an 
area of interest. To better understand the dynamics of the polymer accumulation with 
altering thermal dose, groups were selected for larger accumulation profiles. Thus, for 
additional experiments, four groups were selected to be observed over an 8 h period. These 
included 43°C/10 min to serve as a control, 46°C/10 min since it had an unexpected drop, 
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46°C/30 min as this is where the accumulation increased again and finally 49°C /10 min as 
this group also exhibited increased accumulation.   
It was initially hypothesized, as accumulation is known to be transient, that for the 
46°C/10 min group, the accumulation and washout was accelerated with the increased 
thermal dose from 43°C groups. However, when the thermal dose is increased further, there 
is a threshold for damage within the tumor vasculature which has an effect of the washout 
of these polymers. Thus, for the higher thermal dosed groups (46°C /10 min and both 49°C 
groups), this damage was probably generated which led to prolonged retention observed. 
To test this hypothesis, the four groups were selected to be examined for 8 h accumulation 
profiles and histological analyses (Figures 3.3-3.5).  
It was hypothesized that for 46°C/10 min the influx and washout would be 
accelerated shifting the peak accumulation to an earlier time point. As can be seen in Figure 
3.3, the data supports that hypothesis. For 46°C/30 min, the accumulation at 2 h was much 
greater, likely due to further increased flow within the tissue from increasing the duration 
of heating and thermal dose. The polymer accumulation is then retained over the 8 h time 
period and does not return to baseline likely due to vascular damage being initiated. For 
49°C/10 min, the polymer accumulation at 2 h is not as high but was retained within the 
tissue over time as the thermal dose was increased. The residual retention over the 8 h time 
period observed in both of these treatment groups is likely due to damage of the vasculature 
at a certain threshold that limits clearance or washout.  
When the polymer accumulation of 8 h is examined as AUC, the total exposure of 
polymers within the tumor, there is no significant difference between 43°C/10 min and 
46°C/10 min. The AUC for 46°C/30 min does have a significantly larger increase which 
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then drops back down when the thermal dose is further increased to 49°C/10 min (Figure 
3.4). This decrease in AUC can possibly be explained by the fact that the threshold for 
generating vascular damage is achieved much sooner for the 49°C/10 min group. For 49°C 
/10 min, the induction of vascular damage occurs at a faster rate and limits the amount of 
polymer that can be delivered to the tumor site. Likely the burst accumulation is what is 
being “trapped” in these treatment groups. Therefore, the polymer accumulation is only 
slightly enhanced before the flow is obstructed whereas, for 46°C/30 min, the damage is 
generated at a later point after the polymer accumulation is enhanced.  
To summarize, as thermal dose increases, the flow within the tumor vasculature 
increases leading to more polymer extravasation as does the rate of vascular damage. When 
this damage is initiated later, the polymers that were accumulated become trapped, but if 
the damage occurs too soon, the polymers do not have a chance to enter the tumor tissue 
and so accumulation or tumor AUC is decreased. Thus, there is an optimal window for 
enhancing delivery of macromolecular polymer conjugates and subsequently trapping 
them within the tumor tissue. This data shows that, of these groups, 46°C/30 min has the 
greatest polymer accumulation over the 8 h period and is the optimal thermal dose for this 
application. 
The previous data supports the hypothesis of altered dynamics with changes in 
thermal dose. However, they do not support whether vascular damage is the cause for 
prolonged retention and decrease in AUC for the 49°C/10 min group. With the aid of 
histological analyses it can be concluded that that the prolonged retention seen in 46°C/30 
min and 49°C/10 min (Figure 3.3) of HPMA copolymers can be attributed to the 
vasculature damage due to increased heating dosage as both prolonged retention and 
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vascular damage are only observed in these groups (Figure 3.5). Vascular damage is indeed 
a factor in the polymer accumulation profiles observed previously leading to longer 
retention or slower washout. 
When the data for polymer accumulation is displayed on the same scale as a thermal 
dose equivalent (Figure 3.6B and 3.6C), the trends of increasing temperature and duration 
can be visualized more easily. In Figure 3.6B, it is observed that there is a trend, although 
some consecutive points are not statistically significant, for accumulation at 4 h with 
increasing dose which can be explained by the previously presented findings. As the 
thermal dose (time at 43°C) increases from about 10 s to 10 min, the accumulation at 4 h 
increases. After this point, the accumulation begins to decrease as thermal dose increases 
from 10 to 80 min. This is likely due to the accelerated influx and washout shifting the 
peak accumulation to earlier times (e.g., 2 h post treatment). As thermal dose continues to 
increase to 240 min, the accumulation enhancement increases again, most likely due to 
accelerated flow dynamics but more importantly vascular damage restricting washout of 
accumulated polymers. However, as the thermal dose is increased from 240 to 640 min the 
induction of vascular damage occurs at a faster rate and limits the amount of polymer that 
can be delivered to the tumor site. Likely the burst accumulation is what is being “trapped” 
in these treatment groups. 
Next, the AUC of Figure 3.4 was additionally plotted against the thermal dose 
equivalent to each treatment group to better present the effects of altering the heating 
regimen (Figure 3.6C). As the dose increases from 10 to 80 min the AUC does not change, 
indicating that although the flow may be accelerated shifting peak accumulation to earlier 
times, the overall polymer exposure within the tumor tissue has not changed. As thermal 
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dose further increases to 240 min, the AUC drastically rises. This is likely 2-fold from 
increased vascular dynamics and the subsequent onset of vascular damage. It should also 
be noted that between 80 and 240 min there exists a threshold at which the thermal dose 
will induce vascular damage within the tumor. There is then a drop in AUC for the last 
group when the dose reaches 640 min. This can likely be attributed to the onset of vascular 
damage where at 240 min the damage occurs more slowly and allows for more polymer 
accumulation while at 640 min this event occurs faster restricting the amount of polymer 
influx.  
The accumulation data suggests that there are two threshold temperatures: one at 
which to achieve significantly enhanced delivery and a second to create vascular damage 
within the tissue. The vascular damage can be correlated with increased retention times 
within the tumor, or slower washout, with histological analyses supporting that this 
vasculature damage is seen only in groups exhibiting this characteristic. This data supports 
the hypothesis that increasing the thermal dose beyond what has been used previously can 
further enhance the delivery of polymer conjugates along with longer retention times 
within the tumor tissue. The groups that are shown to achieve this effect are 46°C for 30 
min (t43 = 240 min), 49°C for 10 min (t43 = 640 min), and 49°C for 30 min (t43 = 1920 min). 
Although 46°C for 10 min (t43 = 80 min) was increased beyond the previously used t43 = 
10 min, the ability to further enhance delivery was not observed. This suggests that there 
is a maximal exposure which can be produced below the vascular damage threshold. 
Beyond the thermal dose at which this threshold is achieved there can be improvements in 
polymer exposure within the tumor. However, raising the thermal dose too much beyond 
240 min can have negative effects as well, hindering further accumulation. Therefore, there 
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must be a balance between increasing flow within the heated area and then triggering 
damage later on. Of the groups that were tested in this study, 46°C for 30 min (t43 = 240 
min) was able to achieve this goal. Polymer accumulation was significantly enhanced and 
eventually induced the damage “trapping” the previously accumulated polymers.  
The results of these experiments have additionally shown to be consistent with 
previous work examining the thermal threshold for tissue damage. For thermal damage to 
be induced with different temperature groups used here, 43°C would need to be applied for 
around 600-700 min, 46°C for 40-50 min, and 49°C applied for around 9-10 min [33]. 
Similarly, we found this to also be true where the 43°C groups had no signs of damage as 
the amount of time spent at this temperature was nowhere near 600-700 min. For 46°C, the 
10 and 30 min groups both showed increasing amounts of thermal damage respectively as 
the thermal dose gets closer to the threshold around 40-50 min. Finally, much larger 
amounts of damage are observed for 49°C at 10 min, consistent with this being at the 
thermal threshold for tissue damage. These prior data support our current findings showing 
that a thermal dose at or just under the thermal threshold is best for enhancing delivery of 
polymer therapeutics and that the induction of vascular damage does play a role. 
Additional mechanistic understanding is desired to visualize and determine the 
exact effects these different heating regimens have on vascular dynamics. Knowing what 
to expect in response to different heat treatments can possibly lead to better design of 
nanomedicines and macromolecular drug conjugates to take advantage of specific events 
that are taking place. It is unknown exactly if tumor blood flow and vascular damage are 
the only responsible functions affecting the delivery and accumulation. Thus, experiments 
with the use of intravital microscopy to observe changes in vascular dynamics and tracking 
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of fluorescent polymer accumulation in vivo would further aid in understanding the 
mechanisms that determine enhanced drug delivery with hyperthermia. 
Distribution of gold nanorods throughout the tumor tissue is another area of interest. 
The accumulation of GNRs by the EPR effect may not be homogeneous resulting in a 
nonhomogenous distribution of heat when the laser is applied. Along with tissue 
attenuation of the laser light, it is likely that there is temperature distribution within the 
tumor tissue. Here, only a single point measurement was recorded via a needle 
thermocouple. Additional temperature imaging methods (i.e., magnetic resonance 
thermometry) should be considered to determine if there is homogenous distribution of 
heat and heating profile variability from animal to animal based on GNR distribution. 
Another potential factor that could lead to a greater influx of fluid and enhanced polymer 
delivery is that areas adjacent to GNRs cause local regions of dehydration and reduced 
interstitial pressure. It has been previously shown that hyperthermia is able to reduce the 
interstitial fluid pressure [34] and would, therefore, be of interest to see if this leads to 
enhanced delivery that is dependent on local GNR distribution throughout the tumor tissue. 
To study this effect on local tumor accumulation intravital microscopy could be used along 
with methods to correlate changes in interstitial pressure with polymer accumulation over 
time.  
Finally, it would be worth studying if the same thermal dose from different heating 
parameters such as 43°C/640 min and 49°C/10 min can achieve the same effects on 
polymer accumulation. Although this cannot be definitely confirmed by the current studies, 
the expected results may be extrapolated. If 43°C were extended to longer times, the overall 
thermal dose would increase, but the time it takes to reach the thermal damage threshold 
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would be much longer than the time it would take at 49°C to reach the same threshold. 
With this longer time, the damage would occur at a slower rate and allow for greater 
amounts of polymer accumulation. For the same thermal dose of 43/640 min vs. 49/10 min, 
it would be expected that more polymer accumulation would occur for 43/640 min. 
However, the heat treatment would have to be for 640 min or 10.6 h which is not likely to 
be logistically possible. There are obviously trade-offs for each heat treatment with the 
same thermal dose and so a balance must be considered. It is believed that the best 
treatment would increase the amount of polymers in tumor tissue with increased vascular 
dynamics but then eventually reach the thermal dose equivalent to induce vascular damage 
in order to “trap” the polymers for longer periods of time. As such we have shown that 
46°C for 30 min is able to achieve such a desired outcome.  
Drug delivery applications for the treatment of different solid tumors can 
potentially benefit from using heating regimens that take advantage of these aspects. Mild 
hyperthermia is considered to be mild heating varying anywhere between 40-46°C applied 
for differing lengths of time. This type of heating is only aimed to transiently enhance 
delivery but also affect cellular mechanisms that can sensitize the cells to an adjuvant 
therapy. Above 46°C the therapy is considered to be ablative causing direct tissue necrosis 
and coagulation [35]. Methods have been steadily improved upon to achieve noninvasive, 
selective, and uniform heating throughout the tumor. With the ability to localize the heating 
to the target site one can potentially mildly heat the tumor to increase perfusion and 
permeability. While this is happening, a macromolecular drug conjugate can be 
administered and be significantly delivered to the heated tumor. After this event has 
occurred, the power or temperature could be further increased to ablate the tumor tissue. 
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This would trap the therapeutic agent, be it chemo- or radiotherapy, and reduce significant 
washout.  
In clinical hyperthermia treatments, 43°C or lower is most commonly used for 
cancer therapies in order to avoid thermal damage. Hyperthermia has shown its benefits 
for synergistic enhancement of both chemo- [36, 37] and radio-therapies [38, 39] as well 
as in thermally triggered drug delivery systems [40-43]. If a clinician was to use the strategy 
we have proposed here with a treatment at 46°C for 30 min, the higher temperatures may 
possibly damage surrounding tissues. To better assure this does not happen in higher 
thermal dose or even ablative therapies it would be very helpful to know the precision of 
PPTT heat treatment. The optimal system would heat only the tumor tissue that contains 
GNRs while the surrounding tissue would have little to no heating. Using alternative 
imaging techniques it may be possible to observe this effect and better support the use of 
higher temperatures for specifically heating tumors and maximally enhancing polymer-dug 
accumulation while leaving healthy tissues unharmed. Ablative therapies are known to be 
very effective at eliminating cancerous tissue but are also shown to miss a significant 
population of cells at the periphery bordering healthy tissue. In order to fully eliminate 
these cells surviving the heat treatment, an adjuvant therapy can be used to clean up what 




Altering the heating regimen for treatment of tumors with GNR mediated PPTT for 
enhancing polymeric drug delivery can create different accumulation profiles. Of the 
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groups that were tested, 46°C for 30 min had a significantly larger amount of accumulation 
over time. The changes can be attributed to damage of vasculature within the tumor and 
possibly greater blood flow in the tissue. Altering the heating parameters of PPTT can 
change the accumulation profiles of untargeted HPMA copolymers in the tumor tissue. 
This is shown by enhanced damage to tumor vasculature leading to longer retention times. 
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HIGH INTENSITY FOCUSED ULTRASOUND HYPERTHERMIA FOR  
ENHANCED MACROMOLECULAR DELIVERY 
 
4.1 Introduction 
 Many conventional chemotherapeutics exhibit less than 1% accumulation of the 
injected dose (ID) within solid tumors [1]. This can be attributed to poor water-solubility, 
short circulation half-life, and biological barriers hindering extravasation and penetration 
[2]. To overcome these issues, nanomedicines have been developed to increase site-specific 
accumulation through passive targeting by the enhanced permeability and retention (EPR) 
effect and through active targeting strategies to ultimately improve efficacy. Although 
improvements have been observed with these systems, the increased accumulation is 
marginal at best where <5% ID localizes within the tumor [1]. Ways to further enhance the 
delivery of nanomedicines include augmentation of the EPR effect with the use of vascular 
mediators or mild hyperthermia to increase blood flow and vascular permeability [3]. 
Hyperthermia has been used as a combination therapy to further increase the delivery of 
targeted nanomedicines and enhance the efficacy of chemotherapy [4]. This is
Reprinted in part with permission of Elsevier. N. Frazier, A. Payne, J. de Bever, C. Dillon, 
A. Panda, N. Subrahmanyam, H. Ghandehari, High intensity focused ultrasound for 




accomplished by increasing blood flow in the heated tumor tissue while also dilating the 
tumor vessels, further expanding the fenestrae and allowing for greater extravasation. 
Methods to selectively heat the tumor tissue include radiofrequency ablation (RFA), 
magnetic fluid hyperthermia (MFH), gold nanoparticle mediated laser therapy, and high 
intensity focused ultrasound (HIFU). Previously, our lab utilized gold nanorod (GNR)-
mediated plasmonic photothermal therapy (PPTT) to enhance the delivery of water-soluble 
HPMA copolymers. This method was shown to be effective in improving delivery [5], 
tumor penetration [6], and efficacy [7] against prostate cancer xenografts. However, the 
application of heat through this method is limited by several factors. Delivery of gold 
nanoparticles to the tumor site mainly depends on the EPR effect which may not be 
exhibited in all tumors and tumor types [2], and can limit the heating capacity in methods 
that require nanoparticle accumulation by this route. Systemic administration of gold 
nanoparticles leads to long-term accumulation in filtration organs, such as the liver and 
spleen, as a majority of the GNRs accumulate in these tissues (>90%) as opposed to the 
tumor tissue [8]. The potential adverse effects over time of this off-target accumulation are 
not fully understood, potentially hampering their translation to the clinic. Additionally, the 
limited penetration depth of light reduces the utility of GNR-mediated mild hyperthermia 
to superficial tumors. Alternative methods are needed to generate mild hyperthermia to 
enhance delivery of nanomedicines.  
One such method is high intensity focused ultrasound (HIFU). This method 
generates heat without the insertion of a probe as with RFA or prior injection of 
nanoparticles as with MFH or PPTT. HIFU produces heat within the body through focusing 
ultrasound waves to a focal point creating an intense deposition of energy that can cause 
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change at the cellular level using both thermal and mechanical effects. This phenomenon 
can cause heating in tissues resulting in hyperthermic or ablative effects. Using phased-
array transducers with multiple transducer elements, the focal point can be electronically 
phased to compensate for the acoustic properties of different tissues and create subject-
specific heating patterns [9]. HIFU additionally allows for heating with a high degree of 
temporal control, as the rate of heating depends on the magnitude and duration of the 
ultrasound exposure [10]. While HIFU has been performed under ultrasound and magnetic 
resonance imaging (MRI) guidance, MRI provides excellent soft tissue contrast as well as 
the ability to monitor the temperature rise in real time through MRI thermometry. 
Integration of MR guidance during HIFU exposure allows for simultaneous imaging to 
guide the treatment and MR thermometry to monitor the temperature and provide real time 
feedback [11, 12]. 
One challenge of HIFU in comparison to the other methods of heating is that the 
focal zone does not preferentially heat the tumor tissue and needs to be guided to the tumor 
site through MR or ultrasound imaging prior to treatment. The HIFU focal spot also has a 
relatively small, ellipsoidal focal zone, on the scale of a few millimeters (e.g., 1-3 x 3-8 
mm), and needs to be moved throughout a larger tumor to achieve uniform heating [13]. 
Electronic beam steering or physically steering the transducer can be used in combination 
with real time temperature mapping by MR thermometry to heat the pathological tissues at 
a predefined temperature over a certain length of time [14]. This MR-guided HIFU 
(MRgHIFU) technology platform is currently Food and Drug Administration (FDA) 
approved for thermal ablation of uterine fibroids, treatment of bone metastases, and for 
treatment of prostate cancer [15], but has potential applications in temperature-induced 
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local drug delivery with hyperthermia [16] and other ablative therapies in oncology (i.e. 
breast, prostate, liver, brain) [17]. Because of these attributes, HIFU has emerged as an 
effective modality for drug delivery applications. 
The aim of this work was to create an MRgHIFU controller system to uniformly 
heat tumor tissue in a subcutaneous mouse tumor model at approximately 43°C and further 
enhance the delivery of macromolecules. Ex vivo techniques were first used to evaluate the 
MRgHIFU controller system and determine treatment parameters that would achieve 
uniform hyperthermia. These parameters were then translated to the in vivo model. The 
ability to enhance delivery of macromolecules including Evans blue dye (EBD) bound to 
albumin and HPMA copolymers was evaluated.  
 
4.2 Materials and methods 
4.2.1 Synthesis and characterization of HPMA copolymers  
HPMA was synthesized and confirmed by NMR [18] and 
aminopropylmethacrylamide-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(APMA-DOTA) was synthesized and confirmed by mass spectroscopy  [19].  Free radical 
precipitation copolymerization with a feed ratio of 90 mol% HPMA and 10 mol% APMA-
DOTA using azobisisobutyronitrile (AIBN) as the initiator in methanol at 50°C for 24 h 
was used to prepare the copolymers. The product was then precipitated and washed with 
diethyl ether followed by dialysis against deionized water to remove unreacted 
comonomers and initiator. The copolymers were lyophilized to obtain the final product. 
Weight average molecular weight (Mw), number average molecular weight (Mn), and 
polydispersity index (Mw/Mn) were estimated by size-exclusion chromatography (SEC). 
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APMA-DOTA comonomer was included in copolymerization for the ability to chelate 
Gadolinium (Gd).  
The resulting copolymer was then dissolved in deionized (DI) water with Gd (III) 
acetate hydrate (1.2 mol equivalent to APMA-DOTA) and the pH was raised between 5.0 
and 5.5. The solution was stirred overnight for 16 h followed by addition of 
ethylenediaminetetraacetic acid (EDTA) to remove excess Gd (EDTA:GD, 1:1). The 
product was then dialyzed against 0.9% saline and lyophilized. Mw, Mn, and Mw/Mn were 
estimated by SEC. The amount of chelated Gd and free Gd was determined by inductively 
coupled plasma mass spectrometry (ICP-MS). Chelated Gd and free Gd were separated 
using a disposable size exclusion PD10 column and the different fractions were analyzed 
by ICP-MS to determine purity.  
The longitudinal relaxivity (T1) of the copolymers was characterized and compared 
to previously synthesized Gd-chelated copolymers [6, 19, 20]. Four different 
concentrations of Gd (0.1 to 0.015 mM Gd) were prepared in DI water and placed in a 
Bruker BioSpec 7.1 T horizontal bore MRI. T1 values were measured by an inversion 
recovery fast spin-echo imaging sequence using inversion times of 50, 100, 300, 500, 800, 
1000, 2000, 4000, 7000, and 8000 ms, echo time (TE) of 4.2 ms, and repetition time (TR) 
of 12000 ms. T1 for each vial was calculated using Bruker software and the relaxation rate 
(R1 = 1/T1) was plotted against Gd equivalent concentration. The relaxivity was measured 






4.2.2 Stability of HPMA copolymer-Gd conjugates 
HPMA copolymer-Gd conjugates were dissolved in mouse serum and incubated at 
43°C for 10 min followed by incubation at 37°C for a total of 72 h. Samples were analyzed 
at 10 min, 24, 36, and 72 h and run on a PD10 column to separate free Gd from HPMA 
copolymer-Gd conjugates. The fractions were then analyzed by ICP-MS for Gd content. 
The amount of free Gd was compared to that of the chelated HPMA copolymer-Gd fraction 
to determine the percent of free Gd over time.  
 
4.2.3 MRgHIFU controller system and ex vivo evaluation 
All heating was performed using an MRgHIFU small animal system (Image Guided 
Therapy, Inc., Bordeaux, France. 16-element annular transducer, f=3MHz, 1x1x3 mm full-
width-half-maximum focal spot size, +/- 1.5 cm steering along beam direction) placed in a 
Siemens 3T Trio MRI scanner. Because the phased-array transducer has an annular design, 
in plane focal spot motion was achieved by physically moving the transducer through the 
use of piezoelectric motors. The experimental setup is shown in Figure 4.1A. To determine 
MRgHIFU heating parameters that would produce stable hyperthermic conditions, 
different combinations of ultrasound power, heating trajectory shape, and speed were 
evaluated in an ex vivo chicken breast model. To best mimic the conditions required for the 
in vivo model, uniformity of heating over a 10 x 10 mm region of interest (ROI) was 
evaluated for each parameter set and the combination of parameters that produced a 
spatially uniform and stable temperature rise of 43°C over a 10-min period were identified. 
Temperatures were assessed in real time using the proton resonance frequency shift MR 


















Figure 4.1: (A) Ex vivo experimental setup using chicken breast as a tumor phantom 
model. (B) Heating pattern for producing uniform heating.  
A B  
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sequence (TR/TE = 150/13 ms, echo-train length (ETL)=9, 1.2 s acquisition, 2x2x3 mm 
resolution, 3 slices). Susceptibility effects due to ultrasound transducer motion were 
mitigated using an atlas-based reconstruction [22] where approximately 50 baseline library 
images were acquired with the transducer moving along the defined trajectory (Figure 
4.1B) multiple times without firing the ultrasound. During sonication, the current MR 
phase measurement was subtracted from the baseline library phase image that was most 
similar in a least squared difference sense. An ROI was defined which excluded the heated 
region in the computation of least squared difference. With the best-matched reference 
image determined, the phase difference, Δ𝜙, was computed and converted to a temperature 




    (1) 
where γ is the gyromagnetic ratio of hydrogen, B0 is the static magnetic field strength, TE 
is the echo time parameter, and α is a tissue proportionality constant which is 
approximately 0.009 ppm/°C for most soft tissues.  
During sonication, the maximum and mean temperature in the heated region was 
monitored. The technician was able to adjust the ultrasound power output trajectory in real 
time using a user interface written in Matlab. A target maximum temperature rise of 43°C 
was selected to induce mild hyperthermia but not ablation.  
 
4.2.4 In vivo tumor model 
 In vivo experiments were carried out using CD1 mice containing two S-180 
subcutaneous tumor xenografts, one on each flank. Inoculations were performed by 
injecting 200 μL of phosphate buffered solution (PBS) containing 10x106 cells 
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subcutaneously and allowing tumors to grow for 10-14 days to reach 7-10 mm in diameter. 
Once the tumors reached their desired size, they were then treated with HIFU hyperthermia.  
 
4.2.5 In vivo MRgHIFU heating 
 Prior to HIFU treatment, the mice were anesthetized (2% isoflurane), and tumor 
regions were shaved and swabbed with a depilatory cream to remove all hair surrounding 
the tumor region. Immediately before heating, a needle thermocouple was inserted into the 
center of the tumor and 2 min of temperature data were obtained to determine a baseline 
tumor temperature. The mouse was placed in the same MRgHIFU small animal system as 
described above. The setup is shown in Figure 4.2 with an axial and coronal image. The 
mouse was placed on an agar mold with the tumor placed in an access hole. The agar mold 
provided a large region to obtain MRI phase measurements to improve the temperature 
measurement with atlas-based reconstruction. A custom two-channel radiofrequency coil 
was placed on top of the animal, and a small animal monitoring system was used to monitor 
the animal (respiration and temperature, SA instruments, Inc.). Similar to the ex vivo 
studies, MR temperatures were monitored using the 2D seg-EPI sequence (parameters 
above).  
  During sonication, the maximum and mean temperature in the tumor was 
monitored. Using the MRgHIFU controller, a power range between 3.3 and 5.6 W was 
implemented (approximately 3.5 to 4.6 MPa in water) to achieve a maximum temperature 
rise of 43°C. Temperatures were temporally filtered for respiratory artifact using a low pass 























Figure 4.2: (A) Axial image of small animal MRgHIFU system used to 
heat tumor tissue in vivo. (B) Coronal image of in vivo setup with the 
treated tumor surrounded by the agar mold. 
A B  
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4.2.6 Evans blue dye accumulation 
 MRgHIFU was used to treat one S-180 tumor for each of the five CD1 mice. The 
second S-180 tumor was left untreated and used as an internal control. EBD was injected 
intravenously through the tail vein at a dose of 10 mg/kg dissolved in 0.9% sterile saline. 
Immediately after injection, one subcutaneous tumor was treated with MRgHIFU to 
achieve uniform heating of approximately 43°C for 10 min. Five hours after treatment, the 
animals were sacrificed and the tumors removed and weighed. The tumors were then 
placed in 1.5 mL of formamide for 48 h at 60°C to extract the EBD from the tissue. The 
EBD leaches into the surrounding media and is analyzed by measuring the absorbance of 
the solution at 620 nm. Absorption was normalized by tumor mass and the ratio of treated 
to untreated tumor accumulation was calculated to determine the thermal enhancement 
ratio (TER) which corresponds to increase in macromolecular delivery. To investigate the 
ultrasound’s mechanical effect on tumor accumulation of EBD separately from the thermal 
effects, 5 CD1 mice with S-180 tumors were treated with MRgHIFU, but only to a target 
temperature of approximately 37 °C (normothermia). 
 
4.2.7 Gadolinium polymer accumulation 
 MRgHIFU was again used to treat one of two S-180 tumors in three CD1 mice. 
Immediately after heat treatment, an axial image slice including both tumors was recorded 
as a baseline. Quantitative T1(spin-lattice relaxation time) data maps were acquired using 
a Modified Look-Locker Inversion Recovery imaging (MOLLI) [23] sequence (TR/TE = 
912/1.58 ms, 0.8x0.7x3.5 mm resolution, 35° flip angle, nonselective inversion recovery 
with inversion times of 169/249/329 ms). The animal was then injected intravenously with 
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HPMA copolymer-Gd conjugates (0.03 mmol Gd/kg) in 0.9% sterile saline and imaged 
every 15 min for 5 h post heating. This was done to collect accumulation data of the 
HPMA-Gd copolymer conjugates over time. HPMA-Gd copolymers were injected after 
the heating as opposed to immediately prior since heating was measured by MR 
thermometry. Injecting HPMA copolymer-Gd would dynamically change the T1 signal 
adversely influencing the MR temperature images. The images collected from MR imaging 
were then analyzed to determine the change in signal over the 5-h time period. 
 
4.2.8 Image analysis 
 T1 images were analyzed using Matlab software to determine the mean T1 values 
within the tumor ROI. A Matlab code was generated to select the ROI for both heated and 
control tumors within the MOLLI images and separate ROIs were created for each slice 
and time point. Mean T1 and R1 (1/T1) values were determined over each ROI at each 
time point. Heated and control tumor ΔR1 values were plotted individually and averaged 
with standard deviation (STD) reported. 
 
4.2.9 Statistical analysis 
 Statistical analyses were performed in GraphPad Prism. Comparisons between two 
groups (treated and control tumors), were performed by t-test for each group, P < 0.05 were 
considered statistically significant (* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001). Data was 






4.3.1 HPMA copolymer synthesis and characterization 
The HPMA copolymers were synthesized by free radical precipitation 
copolymerization to be greater than 45 kDa to have a size slightly above the renal threshold 
and take advantage of the EPR effect as well as to be consistent with the size of polymers 
used in previous accumulation studies [6, 24, 25]. Copolymers included DOTA in the side 
chains for chelation of Gd. The attached amount and purity of HPMA copolymer-Gd was 
confirmed by determining the elution volumes of free and chelated Gd and measured by 
ICP-MS. The Mw was estimated to be approximately 51 kDa with a polydispersity of 1.67 
characterized by SEC. The relaxivity was calculated to be 46.8 s-1 mM Gd-1 and a Gd 
content of 0.139 mmol/g of polymer. The percent of free Gd was determined over time 
after first incubating the copolymer conjugates at 43°C for 10 min and then 37°C for the 
remainder of the 72 h. At 10 min, 24, 48, and 72 h, the solution was sampled and free Gd 
was separated from HPMA copolymer-Gd by PD10 column and each fraction analyzed by 
ICP-MS. Approximately 1% of free Gd was detected over the 72-h period with no 
significant changes over time.  
 
4.3.2 MRgHIFU controller ex vivo evaluation 
The combination of ultrasound parameters which met the standards required for 
maintaining hyperthermia at 43°C for several minutes in an excised chicken breast model 
was a concentric square spiral pattern (Figure 4.1B) executed at a speed of 2 mm/s and an 
acoustic power of 3 acoustic W. The distribution was approximately uniform throughout 









Figure 4.3: MRgHIFU controller evaluation in ex vivo chicken breast: (A) Coronal 
temperature maps over time during heating. (B) Mean temperature rise over time within 






state of approximately 6°C for about 5 min (Figure 4.3B). The same pattern was used for 
all tumors in vivo adjusted for tumor size with a speed of 2 mm/s and an initial power 
output of 3 W. 
 
4.3.3 In vivo MRgHIFU heating 
As expected, the translation of the ex vivo results to the in vivo model required some 
modifications to the MRgHIFU protocol. Specifically, as these tumors are subcutaneous 
and the mice are anesthetized, the tumor temperature is not well-regulated and therefore 
the tumor baseline temperature is closer to 30°C when assessed via thermocouple before 
HIFU heating. In order to reach hyperthermia, a rise of approximately 13°C was required. 
With the use of the real time atlas-based MR temperature feedback and variable control 
over transducer power, tumor temperature was controlled to hyperthermic conditions in a 
reproducible fashion (Figure 4.4). Figure 4.4 shows the temperature response achieved in 
the five treated animals. The mean temperature response was maintained between 42-44°C 
in the treated tumors meeting the hyperthermia requirements. 
 
4.3.4 Evans blue dye accumulation 
When tumors are treated with MRgHIFU hyperthermia, changes occur in the 
heated tumor when compared to the nonheated tumor. These changes can include an 
increase in blood flow and vascular permeability leading to greater macromolecular 
accumulation and increased extravasation through the blood vessels. As seen in Figure 
4.5, the tumors that were heated with MRgHIFU hyperthermia had a significant increase 






Figure 4.4: In vivo MRgHIFU hyperthermia heating. (A) Five animals are shown 
that achieved uniform heating in the tumor region (Coronal MRI temperature 
maps). (B) Average temperature data from animals treated with HIFU 


















Figure 4.5: Thermal enhancement ratio of 
EBD with HIFU hyperthermia versus HIFU 
that does not achieve heating (normothermia) 
5 h post treatment.  
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normothermia. This result shows that ultrasound exposure alone did not enhance the 
delivery of EBD and that the increased accumulation was due to the thermal contribution 
of hyperthermia generated by HIFU. It also demonstrates that MRgHIFU hyperthermia 
possesses the capability to additionally enhance the delivery of other nanomedicines 
through the same mechanisms of action. 
 
4.3.5 HPMA copolymer-Gd accumulation 
Gd-chelated HPMA copolymers were administered to CD1 mice bearing two 
tumors to evaluate their accumulation. Figure 4.6A shows a representative result obtained 
from one mouse over the 5-h imaging period. The bottom tumor ROI is the heated tumor 
and the left ROI is the control tumor. As observed in these images, the T1 values of the 
heated tumor decreased over time. The shift from higher to lower T1 values is indicative 
of HPMA copolymer-Gd accumulation as the presence of Gd shortens the T1 relaxation 
times and leads to a lower T1 value. Therefore, the more Gd present in the tumor, the lower 
the T1 value. This can also be visualized in the histograms of Figure 4.6A. The heated 
tumor is represented by the red bars and the control tumor is represented by the blue bars. 
As time progressed, the T1 values for the control tumor did not shift as much to lower T1 
values as did those for the heated tumor. This correlates with larger amounts of HPMA 
copolymer-Gd accumulating in the heated tumor compared to control. This difference is 
presented as ΔR1 in Figures 4.6B and 4.6C. Figure 4.6B shows the individual changes for 
each tumor. Figure 4.6C plots these heated and control tumors as an average and standard 
deviation of the three tumors treated. The same was done for the control tumors. There was 





Figure 4.6: A) Representative montage of three time points of one slice over the 5-h time 
period with histograms of the control T1 values (blue) and heated T1 values (red). B) 
Individual change in R1 values for each heated and control tumor. C) Average change in R1 





hyperthermia treatment.   
 
4.4 Discussion 
This work clearly demonstrates that mild hyperthermia produced by HIFU can 
result in the same increase of accumulation of macromolecules within solid tumors as 
previously demonstrated by using PPTT [5, 6]. In both experiments, the same animal model 
and macromolecules were used to demonstrate this concept. HIFU hyperthermia, like other 
methods of hyperthermia, enhances the delivery of nanomedicines through increased blood 
flow and vascular permeability in the heated tissue leading to increased accumulation of 
macromolecules [3].  
A noninvasive MRgHIFU controller and protocol that heats the tumors evenly and 
maintains hyperthermia for 10 min was developed and the ability for this method to 
enhance macromolecular delivery was evaluated. A controller that can adjust the 
ultrasound power based on the resulting heating profile is critical in achieving the required 
hyperthermic conditions in an in vivo model. Differences in tumor size, morphology, and 
perfusion result in varied acoustic and thermal properties that result in variable thermal 
responses that must be accounted for in real time.  
For proof of concept, EBD was used as a macromolecular marker to track 
accumulation within the heated and control tumor. EBD has been shown to form a colloid, 
about 240 nm in diameter, to which albumin can bind, representing a macromolecular 
system [26]. EBD-albumin accumulates in the tumor tissue due to the EPR effect with an 
additional increase in the heated tissues due to increased flow dynamics and vasodilation 
expanding vascular fenestrae. In previous work using PPTT, EBD was used to determine 
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enhancement of macromolecular delivery in tumors treated with hyperthermia [5]. In this 
work, HIFU hyperthermia demonstrated accumulation of EBD at 5 h post HIFU at 
approximately 1.91 times that of normothermia. These results are similar to our previous 
observation with PPTT that showed thermal enhancement ratio of 1.68 at similar 
hyperthermia conditions [5]. 
HIFU hyperthermia was also evaluated to determine the ability to enhance 
accumulation of HPMA copolymers over a 5-h period. It was observed that after 5 h post 
hyperthermia treatment, there was a significant increase in accumulation when the tumor 
was treated with HIFU versus the tumor left untreated. This is shown by the changes in T1 
signal in Figure 4.6A and in the plots of R1 values in Figures 4.6B and 4.6C. The changes 
in R1 values for the three control tumors and three heated tumors were determined and 
averaged resulting in a mean change of approximately 0.0002 s-1 and 0.001 s-1, 
respectively, at 260 min. This result indicates significantly more polymer accumulated in 
the heated tumors versus the untreated tumors. Previous work with PPTT has also shown 
that Gd-chelated polymers had increased accumulation over 5 h. The results shown here 
with HIFU are additionally consistent with those of PPTT showing that similar effects can 
be achieved. In the previous experiments using PPTT, the control tumors had a mean R1 
value of 1.02 s-1 versus the heated tumors with a mean R1 value of 2.31 s-1 [6]. For both 
experiments, the standard deviations were much higher in the heated groups (either HIFU 
or PPTT) than that of the control groups. If we represent the data as TER, HIFU has 
approximately 5 times the accumulation in the heated tumors than that of the control tumors 
whereas PPTT is approximately 2.3 times higher by this method of visualization using 
MRI. These results indicate the promising ability of HIFU hyperthermia to enhance 
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accumulation of targeted polymer therapeutics. Although the number of animals treated for 
the MRI accumulation study was small (n=3), there is still a significant difference between 
accumulation in the heated tumors versus the control tumors demonstrating the capability 
of HIFU hyperthermia to enhance the delivery of HPMA copolymers. 
This work suggests that HIFU can elicit the same vascular mechanisms that are able 
to enhance accumulation of macromolecules in tumor tissue. Hyperthermia can be effective 
in improving flow throughout these tumors that can overcome some of the biological 
barriers to delivery when significant localized heating is achieved [3]. For small molecule 
drugs with short blood circulation half-lives and low accumulation and residence in the 
tumor tissues, hyperthermia does not significantly improve delivery as the drugs are easily 
cleared from the tissues [27]. With macromolecules, such as albumin or HPMA 
copolymers used in this study, prolonged retention is achieved via the EPR effect as the 
larger sized molecules do not easily escape [28] the vasculature. When hyperthermia is 
used in conjunction with macromolecules that have longer blood circulation times, more 
accumulation over time is observed as the vessels dilate expanding the pores leading to 
greater extravasation, retention, and delivery.  
Although heating via HIFU hyperthermia was performed for only 10 minutes, the 
peak accumulation was observed 4-5 h later. Heat is a physical entity and has damaging 
effects on tumor tissue depending on the temperature of heating and the duration of 
application [25, 29]. Since heat can represent an injurious physical insult, it is likely that 
inflammatory reaction will be involved in the response following tumor heating [30, 31]. 
While the vascular response of mild hyperthermia within the tumor tissue resolves soon 
after heating, mild hyperthermia also creates stress within the tissue that can initiate an 
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acute inflammation and additionally aid in enhanced accumulation of macromolecules for 
several hours. The time frame and nature of the results presented here are consistent with 
protein disaggregation and reassembly. Microtubules of the cytoskeleton have been shown 
to disaggregate during hyperthermia and re-aggregate during subsequent incubation at 
37°C [32]. Endothelial cells have been shown to cause a reversible loss of actin filaments 
that may contribute to increased leakage of tumor microvasculature with recovery after 
hyperthermia occurring over several hours [32]. Thus, the accumulation over the 5 h is 
likely not only due to increased blood flow but also due to the longer lasting inflammatory 
response and recovery of the endothelial cells as the pore sizes return to their original size. 
Besides the vascular mechanisms which have been observed here, mild 
hyperthermia has additionally been shown to induce effects at the cellular level including 
up-regulation of cell surface heat shock protein GRP78 receptor which can be targeted and 
additionally supplement this system to further increase retention of targeted copolymers 
[24]. It is anticipated that our MRgHIFU hyperthermia system can produce these same 
effects as observed before with PPTT. Hyperthermia by MRgHIFU is likely to induce heat 
shock protein expression, enhance the delivery of both targeted and untargeted conjugates, 
and the combination treatment will ultimately result in increased efficacy due to anticipated 
synergism.  
This combination system can likely be applied to any solid tumor that can be 
ablated but in which the tumor margins are sensitive. It is also worth noting that the 
application of both the localized heat treatment and the systemic administration of HPMA 
copolymer-drug conjugates may also have the ability to treat a localized and metastatic 
disease simultaneously. Furthermore, attaching imaging agents to the copolymer 
123 
 
conjugates can provide a theranostic system to see and treat the disease. 
 
4.5 Conclusions 
 An MRgHIFU controller and protocol was developed to heat subcutaneous S-180 
tumors in vivo at 43° for 10 min reproducibly. This method of hyperthermia was then tested 
to observe an enhancement in macromolecular delivery to heated tumors versus unheated 
control tumors. It was observed that HIFU hyperthermia increases the amount of EBD 
accumulation by almost 2-fold at 5 h post heat treatment. Delivery of HPMA-Gd 
copolymer conjugates was also enhanced to a significant degree and visualized by MRI.  
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ENHANCED EFFICACY OF COMBINATION HEAT SHOCK  
TARGETED POLYMER THERAPEUTICS WITH  
HIGH INTENSITY FOCUSED ULTRASOUND 
 
5.1 Introduction 
The ultimate goal of drug delivery is to selectively deliver therapeutics to the 
disease site and allow for increased dosages to be administered to the patient as off-target 
effects are reduced. Polymer therapeutics have been developed in an attempt to accomplish 
this goal for delivery of anticancer drugs to solid tumors [1]. Such constructs can extend 
blood circulation times of conventional drugs and increase accumulation within cancerous 
tissues through passive delivery by the enhanced permeability and retention (EPR) effect 
[2]. The use of these and other nanomedicines has led to improved therapeutic outcomes 
with altered biodistribution in certain cases minimizing side effects (e.g., Doxil reducing 
the cardiotoxicity of doxorubicin) [3]. Still, in the majority of cases only, moderately 
enhanced localization to the tumor tissue is observed, increasing from approximately 1% 
to 5% of injected dose (ID) [4]. The impact of nanoscale delivery systems for treatment of  
Reprinted in part with permission of Elsevier. N. Frazier, A. Payne, C. Dillon, N. 
Subrahmanyam, H. Ghandehari, Enhanced efficacy of heat shock targeted polymer 
therapeutics with high intensity focused ultrasound, Nanomedicine: Nanotechnology, 
Biology, and Medicine, In Press (2016). 
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solid tumors can be limited due to the variability of EPR effect depending on tumor type, 
size, location, and preclinical to clinical correlation [5]. Therefore, combination approaches 
must be considered including augmentation of the EPR effect [6]. 
Methods to further enhance the delivery of nanomedicines through augmentation 
of the enhanced permeability and retention (EPR) effect include mild hyperthermia. At the 
tissue level, this mechanism can both increase blood flow and improve vascular 
permeability by vasodilation [7] leading to improvements in local delivery. Mild 
hyperthermia has been shown to enhance the delivery of nanomedicines to solid tumors 
[8]. At the cellular level, mild hyperthermia has the ability to up-regulate cell surface HS 
receptor glucose regulated protein 78 (GRP78) [9]. Specific peptide sequences have been 
developed by phage display which show a strong binding affinity towards the GRP78 
receptors [10]. These peptides include WDLAWMFRLPVG which have been conjugated 
to polymeric carriers [11]. Methods such as plasmonic photothermal therapy (PPTT), 
magnetic fluid hyperthermia (MFH), and radiofrequency ablation (RFA) can induce 
hyperthermic conditions [8]. We have previously demonstrated that mild hyperthermia by 
gold nanorod (GNR)-mediated PPTT enhances the delivery of N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates containing GRP78 
targeting moieties in the side chains to solid tumors [9]. HS-targeted copolymer-docetaxel 
(DOC) conjugates showed enhanced efficacy when hyperthermia was applied in 
combination [11]. While results of this research are promising, PPTT in combination with 
polymer therapeutics requires a prior injection of nanoparticles delivered intravenously 
which then accumulate in tumor tissue by the EPR effect [12]. The accumulation of these 
particles in tumor tissue allows for laser energy to be locally absorbed [13]. However, after 
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this injection, only a small fraction of the gold nanoparticles reach the tumor site leading 
to a large amount (>90%) of off-target accumulation in other organs such as the liver and 
spleen [12]. In addition in order to heat deep-seeded tumors, a fiber optic needs to be 
inserted in the body. These drawbacks can limit the applications of this promising 
combination strategy. Alternative methods which are noninvasive and provide a higher 
depth of tissue penetration are needed to improve the clinical application of the 
combination of mild hyperthermia and polymer therapeutics to treat solid tumors. 
High intensity focused ultrasound (HIFU) is a noninvasive technique that can 
locally heat tissues and achieve a large penetration depth of up to approximately 20 cm 
through the tissue [14]. We have previously shown that HIFU can be used to generate and 
maintain uniform hyperthermia in tumor tissue and that the resulting thermal effects can 
lead to enhanced delivery of HPMA copolymer-gadolinium conjugates in solid tumors 
[15]. The accumulation of these nontargeted systems enabled a transient increase in 
copolymer concentration in a mouse sarcoma model peaking at approximately 4-5 h post 
HIFU heating [15]. To further build on the utility of HIFU mild hyperthermia in enhancing 
the delivery of macromolecular constructs, in this manuscript, we have used a combination 
of noninvasive HIFU hyperthermia with HPMA copolymer-WDLAWMFRLPVG 
conjugates containing docetaxel (DOC) in the side chains to improve the efficacy of the 







5.2 Materials and methods 
5.2.1 Synthesis and characterization of HPMA copolymer conjugates 
HPMA comonomer was synthesized and confirmed by NMR [16], N-
methacryloylglycylglycyl-2-thiazolidine-2-thione (MA-GG-TT) comonomer was 
synthesized and characterized by NMR, and N-methacryloyl-
glycylphenylalanylleucylglycine-docetaxel (MA-GFLG-DOC) comonomer was 
synthesized and characterized by mass spectroscopy [17]. DOC was provided by AK 
Scientific (Mountain View, CA). Free radical precipitation copolymerization was 
performed using a feed ratio of 82.5 mol% HPMA, 15 mol% MA-GG-TT, and 2.5 mol% 
MA-GFLG-DOC using azobisisobutyronitrile (AIBN) as the initiator in methanol at 50°C 
for 24 h was used to prepare the copolymers. The product was then precipitated and washed 
with diethyl ether three times to removed unreacted monomers. The resulting polymer was 
dried by vacuum desiccation for later use in peptide conjugation.  
The GRP78 targeting peptide WDLAWWMFRLPVG and corresponding 
scrambled peptide RWLWVADPFLMG were synthesized via Fmoc chemistry using a 
Protein Technologies (Tuscon, AZ) PS3 solid phase peptide synthesizer verified 
electrospray ionization mass spectroscopy (ESI/MS). Peptides were then attached to DOC 
containing polymers via activated ester conjugation. The peptide was added to the polymer 
with a molar ratio of 1:1 of peptide to TT content. The peptide and polymer were dissolved 
in minimal amount of dimethyl formamide (DMF) and diisopropylethylamine (DIPEA) 
was then added to make a 10% v/v solution. The mixture was stirred for 24 h under nitrogen 
atmosphere. The polymer-peptide conjugates were precipitated in diethyl ether and washed 
three times by centrifugation to remove DMF. The resulting pellet was dried under vacuum 
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desiccation, dissolved in sodium citrate buffer to prevent hydrolysis of the DOC, and 
dialyzed against sodium citrate buffer to remove free peptides. Weight average molecular 
weight (Mw), number average molecular weight (Mn), and polydispersity index (Mw/Mn) 
were estimated by size-exclusion chromatography (SEC). Peptide content was determined 
by amino acid analysis (AAA).  
Drug release and drug content was determined by high pressure liquid 
chromatography (HPLC) by dissolving 5.0 mg of the conjugate in 200 μl DMSO. 10 μl of 
this solution was incubated in 20 μl buffer A consisting of 0.1 M citrate phosphate buffer 
containing 2 mM EDTA at pH 6.0, 0.6 mM papain and 100 μl of buffer B consisting of 0.1 
M citrate phosphate buffer containing 2 mM EDTA at pH 6.0 and 10 mM of glutathione. 
The mixture was incubated at 37°C for 24 h. An aliquot (50 μl) of the reaction mixture was 
removed and diluted in 450 μl water: acetonitrile (65:35) and evaluated for DOC content 
by HPLC and compared to calibration standards prepared using serial dilutions of DOC in 
the mobile phase. Mobile phase consisted of deionized water (Milli-Q system, Millipore, 
Billerica, MA, USA) and HPLC grade acetonitrile (ACN) using the following gradient: 0 
min, 35% ACN; 15 min, 65% ACN; 25 min, 75% ACN; 30 min 95% ACN; 39 min, 100% 
ACN; 40 min 65% ACN. HPLC analyses were performed with an Agilent Series 1100 
HPLC (Agilent Technologies, Wilmington, DE, USA) equipped with an Alltima C18 5 μm 
150 × 4.6 mm column and a photo diode array detector scanning at 200 – 500 nm. A flow 
rate of 1.0 mL/min was maintained and the sample injection volume was 20 μl. A post time 
of 5 min was used to allow column equilibration between samples. UV absorbance at 230 




5.2.2 Cell culture 
The DU145 human prostate cancer cell line was obtained from ATCC (Manassas, 
VA) and cultured at 37 °C in a humidified atmosphere of 5% CO2 in Eagle's Minimum 
Essential Medium supplemented with 10% fetal bovine serum (FBS). Cells were 
maintained in a logarithmic growth phase during all studies. 
 
5.2.3 In vitro efficacy of heat shock targeted copolymer-drug conjugates 
DU145 cells (3000 per well) were plated in 96-well plates for 24 h. Media was then 
removed and replaced with media containing treatments. Cells were exposed to either heat 
shock targeted copolymers or untargeted copolymers for 12 h at varying concentrations 
between 0 and 1200 nM DOC concentration. One group was incubated at 37°C while a 
second group was exposed to HS (43°C for 30 min) and then incubated at 37°C for the 
remainder of the 12 h. This thermal dose profile was chosen to be consistent with previous 
experiments [11] and as this thermal treatment showed a 4-fold increase in cell receptors 
in vitro [9]. For each treatment case, drug concentrations were varied to include data points 
ranging from approximately 100% to 0% cell viability. Following drug treatment, media 
was removed, cells washed with PBS, growth media replaced, and cells were allowed to 
grow for an additional 60 h (72 h of total experiment duration). Media was then removed 
and cell viability quantified by CCK-8 assay using a SpectraMax M2 microplate ultraviolet 
(UV) spectrophotometer (Molecular Devices, Sunnyvale, CA). Each experiment was 
performed in triplicate, comprising assessment of viability at 10 different drug 
concentrations with 4 samples analyzed per concentration. Relative viability was 
calculated by normalization of UV absorbance against untreated cells. Relative viability as 
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a function of log drug concentration was plotted and nonlinear least-squares regression 
analysis and calculation of IC50 values were performed using GraphPad Prism. 
 
5.2.4 In vivo tumor model 
 In vivo experiments were carried out using nu/nu mice containing two DU145 
human prostate cancer subcutaneous tumor xenografts, one on each flank. Inoculations 
were performed by injecting 200 μL of phosphate buffered solution (PBS) containing 
10x106 cells subcutaneously and allowing tumors to grow for 28-30 days to reach a size 
of 7-11 mm in diameter. Tumor sizes were measured every 3 days using calipers. Once the 
tumors reached their desired size, they were then treated with HIFU hyperthermia. 
 
5.2.5 In vivo MRgHIFU heating 
 Prior to HIFU treatment, the mice were anesthetized (2% isoflurane), a needle 
thermocouple was inserted into the center of the tumor and 2 min of temperature data were 
obtained to determine a baseline tumor temperature. The mouse was then placed in a 
magnetic resonance imaging (MRI)-guided HIFU (MRgHIFU) small animal system 
(Image Guided Therapy, Inc.) in a Siemens 3T Trio MRI. The animal was placed on an 
agar mold with the tumor placed in an access hole. The agar mold provided a large region 
to obtain MRI phase measurements to improve the MRI temperature measurement with 
atlas-based reconstruction. A custom two-channel radiofrequency coil was placed on top 
of the animal, and a small animal monitoring system was used to monitor the animal 
(respiration and temperature, SA instruments, Inc.). MR temperatures were monitored with 
the proton resonance frequency (PRF) method using a 2D seg-EPI sequence (TR/TE = 
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150/13 ms, echo-train length (ETL)=9, 1.2 s acquisition, 2x2x3 mm resolution, 3 slices). 
All heating was performed using an MRgHIFU small animal system (Image Guided 
Therapy, Inc., Bordeaux, France. 16-element annular transducer, f=3MHz, 1x1x3 mm full-
width-half-maximum focal spot size, +/- 1.5 cm steering along beam direction) placed in a 
Siemens 3T Trio MRI scanner. Because the phased-array transducer has an annular design, 
in plane focal spot motion was achieved by physically moving the transducer through the 
use of piezoelectric motors. The experimental setup is shown in Figure 5.1 with an axial 
(Figure 5.1A) and coronal (Figure 5.1B) image. Susceptibility effects due to ultrasound 
transducer motion were mitigated using an atlas-based reconstruction [18] where 
approximately 50 baseline library images were acquired with the transducer moving along 
the defined trajectory (Figure 5.1C) multiple times without firing the ultrasound. During 
sonication, the current MR phase measurement was subtracted from the baseline library 
phase image that was most similar in a least squared difference sense. Using a previously 
described MRgHIFU controller [15], the maximum and mean temperatures in the tumor 
were monitored and a power range between 3.3 and 5.6 W was implemented 
(approximately 3.5 to 4.6 MPa in water) to achieve and maintain a maximum temperature 
rise of 43°C. The technician was able to adjust the ultrasound power output trajectory in 
real time using a user interface written in Matlab. A target maximum temperature rise of 
43°C was selected to induce mild hyperthermia but not ablation. During post processing, 


















Figure 5.1: Schematic of in vivo heating setup. A) Axial image of small animal MRgHIFU 
system used to heat tumor tissue in vivo. B) Coronal image of in vivo setup with the 
treated tumor surrounded by the agar mold. C) Heating pattern for producing uniform 
heating.  
 
A B  C 
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5.2.6 In vivo expression of GRP78 with MRgHIFU hyperthermia 
 MRgHIFU was used to treat one tumor for each of the nu/nu mice (n=3) bearing 
two subcutaneous DU145 tumors. The second tumor was left untreated and used as an 
internal control. Hyperthermia by MRgHIFU was used to induce HS and determine the up-
regulation of GRP78 receptors in the heated tumor versus the control tumor. Eight hours 
following induction of heat shock, the mice were sacrificed and both tumors were removed 
and fixed in 10% buffered formalin. Immunohistochemical analysis of GRP78 expression 
was then performed on paraffin embedded tumor tissue sliced into 4-micron thick sections 
and stained using a goat polyclonal anti-GRP78 antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA). 
 
5.2.7 In vivo efficacy of heat shock targeted HPMA-DOC copolymer 
 conjugates with MRgHIFU 
The combination of HS-targeted copolymer-drug conjugates and MRgHIFU were 
evaluated in vivo using nu/nu mice bearing two subcutaneous DU145 human prostate 
cancer tumors. Prior to treatment with MRgHIFU hyperthermia to one tumor, either saline, 
free DOC (formulated in polysorbate 80:ethanol:saline [20:13:67, v/v/v]), untargeted 
(scrambled peptide) polymer-DOC, or HS-targeted polymer-DOC was injected 
intravenously at 10 mg/kg equivalent of DOC. Each treatment group was comprised of six 
mice. The mice in each treatment group were monitored over 30 days, twice a week for 
changes in tumor volume and animal weight. Tumor dimensions (length and width) were 
measured and tumor volume estimated as length × width × π/6. Normalized tumor volume 
presented as mean ± standard error of the mean (SEM) and changes in animal weight 
136 
 
presented as mean ± standard deviation (STD) as a function of time. After the 30-day study 
was completed, tumors and organs were removed, fixed in 10% buffered Formalin, paraffin 
embedded, sectioned into 4-micron thick slices, and stained with H&E, Ki-67, TUNEL, 
and Caspace-3 to observe tissue morphology, cell proliferation, and apoptosis. 
 
5.2.8 Statistical analysis 
 Statistical analyses were performed in GraphPad Prism. Differences in normalized 
tumor volumes and changes in animal weight were determined by one-way ANOVA. 
Where differences were detected, Tukey’s post test was used to test for significance 
between groups. The default significance level was set at α = 0.05 for all statistical tests. P 
< 0.05 were considered statistically significant (* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001).  
 
5.3 Results 
5.3.1 HPMA copolymer synthesis and characterization 
The HPMA copolymers were synthesized by free radical precipitation 
copolymerization to be greater than 45 kDa to have a size slightly above the renal threshold 
in order to take advantage of the EPR effect as well as to be consistent with the size of 
polymers used in previous accumulation studies [9, 19, 20]. The characteristics of the 
copolymers are summarized in Table 5.1 and size-exclusion chromatographs are shown in 




























Table 5.1: HPMA copolymer-drug conjugate characteristics. 
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5.3.2 In vitro efficacy of heat shock targeted and untargeted polymer-docetaxel 
conjugates with human prostate cancer cells 
The ability of the HS-targeted and untargeted HPMA copolymer-DOC conjugates 
to inhibit the growth of DU145 human prostate cancer cells was first evaluated in vitro. In 
Figure 5.2, both targeted and untargeted conjugates were incubated with and without 
hyperthermia at varying concentrations of DOC. The IC50 for the HS-targeted copolymer 
conjugates and untargeted conjugates under normothermia were 14.9 +/- 3.5 and 16.2 +/- 
4.6 nM, respectively. When the copolymer conjugates were incubated with hyperthermia, 
the IC50 for targeted and untargeted copolymer conjugates shifted to 7.4 +/- 2.3 and 11.0 
+/- 4.6 nM, respectively. It was expected that HS-targeting and hyperthermia would shift 
the IC50 to a lower concentration. 
 
5.3.3 In vivo MRgHIFU heating 
Tumor temperatures were recorded during HIFU hyperthermia treatments and 
mean temperature was plotted as an average of the six mice treated in each group +/- one 
STD (Figure 5.3). Most groups were largely able to heat and maintain at a temperature of 
approximately 43°C during the 10-min period. However, a large amount of variability is 
observed for the tumors heated in the group treated with free DOC and may contribute to 
variability with tumor growth. Saline injected mice were heated and maintained at 
approximately 42°C +/- 2°C (Figure 5.3A), free DOC injected mice were heated at 
approximately 41°C +/- 5°C (Figure 5.3B), untargeted polymer-DOC heated to 
approximately 42°C +/- 2°C (Figure 5.3C), and HS-targeted polymer-DOC heated to 

















Figure 5.2: In vitro efficacy of heat shock targeted and untargeted polymer-docetaxel 
conjugates incubated in combination with A) normothermia (37°C for 72 h) or with B) 
hyperthermia (43°C for 30 min followed by 37°C for 71.5 h). Data is expressed as mean 












Figure 5.3: In vivo MRgHIFU heating temperature profiles of treatment groups A) saline, 
B) free docetaxel, C) untargeted polymer-docetaxel, and D) heat shock-targeted polymer-





5.3.4 In vivo heat shock expression with and without HIFU hyperthermia 
HIFU hyperthermia was used to up-regulate the cell surface expression of GRP78 
in vivo using DU145 human prostate cancer xenografts. After heat treatment to 
approximately 43°C for 10 min, the expression was observed 8 h later by 
immunohistochemical analyses. As seen in Figure 5.4, tumors that were treated with HIFU 
hyperthermia for 10 min (Figure 5.4B) showed much higher amounts of staining for 
GRP78 than did the tumors that were left untreated (Figure 5.4A). This result indicates that 
HIFU hyperthermia by this method has the capability to up-regulate GRP78 receptors in 
vivo. 
 
5.3.5 Tumor growth after combination therapy with HIFU 
In previous work, it was shown that the combination of HS-targeted copolymer-
DOC and mild hyperthermia via GNR-mediated PPTT led to significant tumor reduction 
versus controls [11]. Here we examined if the same could be via HIFU (Figure 5.5). 
Treatment groups of saline, free DOC, and untargeted polymer-DOC were used as controls 
and compared to HS-targeted polymer-DOC. In combination with hyperthermia, the tumor 
growth in each group was slightly more reduced. As expected, saline alone had the largest 
growth (243% of the original tumor size) followed by hyperthermia alone (204%), free 
DOC alone (201%), free DOC with hyperthermia (159%), untargeted polymer-DOC 
(136%), HS-targeted polymer-DOC (119%), and untargeted polymer-DOC with 
hyperthermia (114%). The group with the most tumor size reduction was the combination 
of HS-targeted polymer-DOC with HIFU hyperthermia at 96% the original tumor volume 














Figure 5.4: (A) Control tumor tissue stained for expression of GRP78 cell receptors. 
(B) HIFU hyperthermia treated tumor tissue stained for GRP78 cell receptors 














Figure 5.5: In vivo efficacy of HIFU hyperthermia and heat shock-targeted polymer-
docetaxel. A) Tumor volume over 30 days when injected with saline, free docetaxel (free 
DOC), untargeted polymer-docetaxel (polymer-DOC), or heat shock-targeted polymer-
docetaxel (HS polymer-DOC) with and without HIFU hyperthermia. B) Animal weights 
when injected with saline, free DOC, polymer-DOC, or HS polymer-DOC. C) Treatment 
groups with hyperthermia. D) Treatment groups without hyperthermia. For each treatment 





over the 30-day experiment although the weights of the free DOC group began to drop 
from day 20 to day 30. 
 
5.3.6 Histological analyses of in vivo tumor efficacy  
At the culmination of the 30-day monitoring period, each animal was sacrificed and 
the tumors were removed, collected, and analyzed by histology. Tissues were stained with 
H&E to observe tissue morphology, Caspase-3 to observe apoptosis, and Ki-67 to observe 
cell proliferation. In Figure 5.6, control groups stained with H&E show a higher density of 
cells indicated by the darker color. Additionally, this shows that the HS-targeted polymers 
with hyperthermia had the largest amount of necrotic regions (Fig 5.6). Tissues stained 
with Caspase-3 show cells that have synthesized Caspase-3 in cells undergoing apoptosis. 
This production is indicated by the brown coloration and is most prevalent in tumor tissues 
treated with combination of HS-targeted polymer-DOC and HIFU hyperthermia as 
compared to controls (Fig 5.6). Lastly, tissues stained with Ki-67 show the nuclear protein 
that is present at low levels in quiescent cells but is increased in proliferating cells. 
Positively stained cells are stained brown as well. Again, combination of HS-targeted 
polymer-DOC conjugated and HIFU hyperthermia had the least amount of staining when 
compared to control groups (Figure 5.6). These results additionally show that this 



















Figure 5.6: Histological analyses of tumor tissue treated with saline, free docetaxel 
(free DOC), untargeted polymer-docetaxel (polymer-DOC), or heat shock-targeted 
polymer-docetaxel (HS polymer-DOC) with and without HIFU hyperthermia (HT). 
Tissues were stained with H&E (tissue morphology), Caspase-3 (apoptosis), and Ki-




Previously the Ghandehari lab has utilized GNR-mediated PPTT as a method to 
produce localized hyperthermia selectively in tumor tissue and enhance the delivery and 
efficacy of HS-targeted HPMA copolymer-drug conjugates [9, 11]. Compared to PPTT, 
HIFU has a greater penetration depth (20 cm vs. 2 cm) and is noninvasive where PPTT 
requires a prior injection of nanoparticles delivered intravenously which then accumulates 
in tumor tissue by the EPR effect. After this injection, only a small fraction of the particles 
reach the tumor site leading to a large amount of off-target accumulation in other organs 
such as the liver and spleen [12], and potential long-term effects of this accumulation are 
unknown. Additionally, not all tumors exhibit the EPR effect and those that do can be 
variable [5]. PPTT is still in the early developmental stages whereas HIFU has recently 
been approved by the Food and Drug Administration (FDA) for the ablation of prostate 
cancer tissue [21].  
Mild hyperthermia has been applied to enhance the delivery of other nanomedicines 
including temperature-sensitive liposomal drug carriers [22-25]. However, when these 
liposomal systems are triggered for payload release, the extracellular release of drugs at 
the tumor site occurs. In this case, the free drug can be subject to efflux pumps and hence 
reduced efficacy. Use of polymer-drug conjugates can be more advantageous since the 
mechanism of cellular uptake is endocytosis, prohibiting efflux pumps removal of the drug 
in resistant cancer cases [26]. In addition, covalent attachment of the drug to the polymeric 
side chains reduces nonspecific leakage in the blood stream. Together our results 
demonstrate that the combination therapy of HS-targeted conjugates and HIFU 
hyperthermia has potential for treating prostate cancer and other malignancies. 
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In this work, it is shown that the combination of HIFU hyperthermia with HS-
targeted HPMA copolymer-DOC conjugates leads to improved therapeutic outcome 
against human prostate cancer xenografts in immune compromised nu/nu mice. Here, we 
used HS-targeted HPMA copolymer-DOC conjugates as they have shown a high potential 
for improved therapeutics efficacy in combination with mild hyperthermia [11]. The same 
HS-targeting peptides were also used for comparison keeping all things similar except 
using HIFU instead of PPTT to generate hyperthermia [11]. When comparing the HPMA 
copolymer conjugate characteristics of those synthesized here to those previously used with 
PPTT [11], the Mw was slightly larger here being closer to 100 kDa than those used before 
having an Mw closer to 80 kDa [11]. The drug loading here was slightly less, 
approximately 4.5 wt% compared to 6.5 wt%, and peptide targeting was also slightly less, 
having approximately 14.5 wt% compared to 16 wt% used previously [11]. The conjugates 
were again tested in vitro to determine the IC50 and observe the effects of HS-targeting 
with and without hyperthermia. Without hyperthermia, the IC50 for untargeted and HS-
targeted conjugates were similar but slightly improved for the HS-targeted group. When 
the conjugates were incubated with hyperthermia for 30 min, their IC50s shifted slightly to 
lower concentrations. Hyperthermia is known to sensitize the cells to chemotherapy and so 
it is expected that even the untargeted polymers would be able to see a slight shift in IC50.  
In vivo, it was expected that the use of hyperthermia via HIFU would up-regulate 
the expression of GRP78 receptors on the cell surface. For the HS-targeting strategy to be 
effective, it was important to determine if HIFU hyperthermia had this capability. We 
previously established that this up-regulation occurs between 8-12 h after heating [9]. 
Therefore, tumor sections were analyzed 8 h after treatment with HIFU hyperthermia. The 
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results here show that HIFU hyperthermia does have this capability and is a viable method 
for use to enhance the efficacy of copolymer-DOC conjugates targeted toward these 
receptors. This is expected as HIFU has been shown to increase tumor temperature to 
hyperthermic temperatures and the up-regulation of these receptors is largely due to the 
increased stress on the cells from the increased heat accumulation in the tissues.  
To demonstrate the improved efficacy of the HS-targeted conjugates in 
combination with HIFU hyperthermia, animals were treated with saline, free DOC, 
untargeted polymer-DOC, and HS-targeted polymer-DOC. HS-targeted polymer-DOC 
conjugates showed the greatest reduction in tumor growth versus the saline control without 
hyperthermia. A large amount of variability was seen with the free DOC treated mice. This 
variability may be due to a number of factors including varying tumor size, tumor 
perfusion, and capacity possibly due to the properties of the injected formulation. All of 
these may contribute to improper heating in 2-3 mice leading to large standard deviations. 
The tumor growth plots, however, are again similar to those that used PPTT to generate 
hyperthermia in vivo [11]. However, the extent of tumor reduction was not as great as seen 
with PPTT [11]. This could possibly be due to the slightly lower amounts of drug loading 
and targeting peptide content, or potential ablative effect of GNR to the cells surrounding 
the particles even at mild hyperthermia conditions.  
It must be noted that under the right conditions GNR-mediated PPTT has some 
advantages for inducing mild hyperthermia as well. The selective accumulation in the 
tumor tissue allows for easier application compared with other methods that require 
expensive imaging techniques (e.g., MRI) in conjunction. Simply irradiating the tumor 
region along with healthy tissues will only create heating in the tumor tissue as this is where 
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the GNRs reside. Although the depth of penetration is not as high as other methods of 
hyperthermia such as HIFU, it can be applied to superficial or easily accessible tumors. 
The administration of laser irradiation can easily be altered by adjusting the laser power 
and in turn, tune the temperature without much difficulty. With other methods, obtaining 
uniform heating at the desired temperature may require several adjustments at once. 
However, a distinct advantage of HIFU for inducing mild hyperthermia is the ability for 
deeper penetration of energy and its clinical applicability. 
In clinical applications that use HIFU ablation or surgical resection to treat prostate 
cancer, it may become difficult to ablate or remove the cancerous tissues if they reside near 
important healthy structures including the urethra. The cancer may have begun to invade 
the surrounding tissues becoming difficult to ablate or surgically remove because of 
proximity to these important structures. Therefore, the combination therapy performed here 
may have the capability to completely destroy those areas which are difficult to treat 
otherwise by HIFU ablation alone. Incomplete resection or ablation procedures may result 
in continued cancer growth that may lead to the development of metastatic prostate cancer. 
If this development occurs, the 5-year survival dramatically drops from near 100% to about 
28% with a median survival of about 4 years [27]. Therefore, treatment modalities must 
ensure that these advanced localized cancers are completely eliminated and not allowed to 
further progress. In addition to the survival benefit, the use of this proposed combination 
therapy will decrease complications of incontinence and erectile dysfunction as more 
precaution can be taken leading to a higher quality of life after the cancer is gone.  
As HIFU begins to increasingly be used in the clinic for the treatment of other 
cancers (breast [18, 28], liver [29, 30], pancreas [31, 32]) as solid tumors, so does the 
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capability of this combination therapy shown here. HS-targeting can be used in cancers of 
the liver and breast where the same HS receptors can be targeted [33, 34]. Therefore, this 
treatment option can potentially be applied to a broad range of malignancies.  
 
5.5 Conclusions 
 In this study, it was demonstrated that HIFU hyperthermia can be utilized as a 
tool to selectively heat human prostate cancer xenografts and increase the efficacy of HS-
targeted HPMA copolymer-DOC conjugates. The combination of HIFU hyperthermia 
with these targeted copolymers demonstrates the potential for HIFU to be used as a tool 
to enhance delivery and efficacy of targeted macromolecules.  
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CONCLUSION AND FUTURE DIRECTIONS 
 
6.1 Conclusions 
In this dissertation, the use of localized hyperthermia via gold nanorod (GNR)-
mediated plasmonic photothermal (PPTT) and high intensity focused ultrasound (HIFU) 
was examined for their ultimate use in enhancing the delivery of targeted water-soluble 
polymer-drug conjugates to solid tumors. When detected at an early stage, prostate cancer 
poses limited risk and treatment of stages I-II have a 5-year survival rate near 100% [1] as 
the disease remains localized and surgical resection can provide a cure [2]. However, when 
detected at later stages (stages III-IV), the survival rates begin to drop where stage III has 
a high probability of developing metastases (approximately 50%) [3] leading to a dramatic 
drop in survival to 28% for stage IV where the disease has progressed, spread beyond the 
prostate gland, and metastasized [1].  
The strategy used in this work is aimed to increase the localization of therapeutics 
to the advanced, localized prostate cancer (stage III) in order to eliminate the disease 
entirely and prevent further progression and development of metastases. Ablative therapies 
alone (e.g., noninvasive HIFU) have been shown to be effective in treating localized  
disease [4, 5] but have the potential to leave residual cancerous cells in efforts to minimize 
healthy tissue damage. Chemotherapeutics delivered systemically can provide the strategic
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benefit of treating and eliminating those cancers that may have been missed but lead to 
severe side-effects and low tumor accumulation. In order to utilize aspects of both 
treatments and improve drug delivery, the combination of localized hyperthermia with 
polymer therapeutics have shown to enhance delivery to prostate tumors through increased 
blood flow, vascular permeability, and with the incorporation of heat shock (HS)-targeting. 
PPTT as a method for local heating was previously shown to achieve this goal enhancing 
delivery [6], penetration [7], and efficacy [8] of HS-targeted N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymers in human prostate cancer tumor 
xenografts. This work has shown promise for treatment of advanced localized prostate 
cancer; however, unresolved issues remain. The first question was whether the use of mild 
hyperthermia at the previously used parameters of 43° for 10 min was optimal for maximal 
polymer accumulation as no other combination of temperature and duration was examined. 
Second was whether PPTT was the best method of heating and if a noninvasive alternative 
could be used to produce similar results of enhanced accumulation. Last was whether this 
alternative method could also enhance the efficacy of HS-targeted polymer-drug 
conjugates toward prostate cancer tumor in vivo. 
In Chapter 3, it was investigated how altering the parameters of GNR-mediated 
PPTT heat treatment could create different accumulation profiles of water-soluble HPMA 
copolymers [9]. Eight different combinations of temperature and duration were tested 
ranging from 40-49°C at durations of 10 or 30 min. Of the groups that were tested, 46°C 
for 30 min had a significantly larger amount of accumulation over an 8-h period. This 
increase was likely due to finding a heating zone where blood flow was increased to a 
greater extent than with a lower thermal dose (43°C for 10 min) and where damage of 
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vasculature occurred at a slower rate within the tumor than with a larger thermal dose (49°C 
for 10 min). This region gives the largest increase in accumulation as it increases the 
amount delivered via vascular mechanisms and then limits the outflow of polymers from 
the tumor tissue due to vascular damage occurring at a slower rate. When the thermal dose 
was increased beyond this “sweet spot”, the vascular damage occurred at a faster rate and 
limited the amount of polymer accumulation.  
In Chapter 4, an alternate method of selective heating of tumor tissue was 
investigated. The most clinically relevant noninvasive heating method in HIFU was 
selected for this work. To heat tumor tissue both uniformly and reproducibly in vivo at 
43°C for 10 min, the HIFU system parameters needed to be altered. This temperature and 
duration was selected to be consistent with previous experiments and ultimately compare 
to results obtained using PPTT. Differences in tumor size, morphology, and perfusion 
results in varied acoustic and thermal properties that lead to variable thermal responses 
accounted for in real time. In this work, a magnetic resonance imaging-guided HIFU 
(MRgHIFU) controller and protocol were developed to produce heating in a controlled 
fashion. The MRgHIFU controller was used to adjust the ultrasound power based on the 
resulting heating profile in coordination with improved real time temperature imaging. 
Once this system was shown to reproducibly produce hyperthermia in tumor tissue, it was 
then used to enhance the delivery of macromolecules and compared to results achieved 
with PPTT. Here it was shown that HIFU hyperthermia can produce similar results with 
enhanced accumulation of Evans blue dye (EBD) nearly doubling that of an unheated 
tumor at 5 h post heating. Accumulation of Gadolinium (Gd)-chelated HPMA copolymers 
was also imaged over a 5-h period leading to a significant increase in accumulation over 
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time. The use of HS-targeting to heated prostate cancer tissues has also been shown to 
further improve accumulation with PPTT. Therefore, HIFU hyperthermia was additionally 
evaluated to show its potential to provide a noninvasive means of heating in this 
combination therapy.  
Finally, in Chapter 5, the use of HIFU hyperthermia was further developed to create 
a more clinically relevant combination therapy with HS-targeted HPMA copolymer-drug 
conjugates. In this work, it was demonstrated that HIFU hyperthermia could be utilized as 
a tool to selectively heat human prostate cancer xenografts and increase the efficacy of HS-
targeted HPMA copolymer-DOC conjugates as compared to controls. When this work is 
compared to that in combination with PPTT, again, a similar result is observed. The 
combination of HIFU hyperthermia with these targeted copolymer-drug conjugates 
demonstrates the potential for HIFU to be used as a tool to enhance delivery and efficacy 
of targeted macromolecules. The combination therapy shows greater promise today as 
HIFU has also been approved by the Food and Drug Administration (FDA) for the 
treatment of prostate cancer [10].  
 
 
6.2 Challenges and future directions 
 
The completion of this work indicates that the combination of HIFU and HS-
targeted water-soluble polymer-drug conjugates can be used to treat prostate cancer. This 
combination therapy can potentially be used for the treatment of clinical advanced 
localized prostate cancer (stage III) that resides close to important tissues which need to be 
avoided by ablative therapies. However, before application in the clinic, critical issues need 
to be addressed.  
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To begin, the HIFU temperature controller used in this work is still not ideal. 
Although a tremendous amount of hard work was done, improvements to the system can 
be achieved. Here, only the ultrasound power parameter was altered during heat treatments 
to achieve mild hyperthermia (43°C). Additional parameters, such as focal spot pattern and 
focal spot speed in different sections within the pattern, can be adjusted during pre-
planning or in real time during the procedure to achieve uniform heating of unusually 
shaped heterogeneous tumors. Tumors are not always perfectly spherical and will require 
different patterns in order to heat uniformly. Irregularly shaped tumors necessitate the 
adaptation of unique patterns. Figure 6.1 gives a few examples of alternative patterns that 
can be used for different shaped tumors by adapting the reduced square spiral pattern. A 
repertoire of patterns as such can be a valuable tool for clinicians and scientists when 
preparing to treat with HIFU hyperthermia. With heterogeneous perfusion and varying 
tissue densities, heat capacity will change in the tissue leading to variability in spatial 
distribution. More specifically, temperatures will be higher in regions that absorb the 
ultrasound energy more readily. In those regions, it may be useful to speed up the focal 
spot movement. In spots that do not absorb well, the focal spot could be slowed down to 
heat at the proper temperature. Lastly, a detailed planning procedure should be developed 
based on pre-imaging. With tumor location (prostate, breast, liver, kidney), shape, overall 
tissue density, and heterogeneity, the parameters mentioned previously can be pre-planned 
to heat and maintain a precise desired temperature uniformly throughout the tumor.   
The work done here was performed in subcutaneous animal models. These models 
provide important insight for investigational treatments but do not accurately depict the 




















Figure 6.1:  Examples of different patterns that can be used in future experiments for 
different shaped tumors. The previously used reduced square spiral pattern can be 
adapted to varying shapes and sizes. 
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matter of a few weeks do not accurately represent the same rates at which tumors grow 
spontaneously in human prostate glands. Therefore, it is difficult to conclude that success 
in a murine model will equal success in humans. The next logical step for this work would 
then be to attempt this therapy in a situation more resembling of a human cancer. To do 
this, an orthotopic model should be used to show that tumors grown within an actual 
prostate gland of a large animal can be treated in a fashion similar to how one in a human 
has been proposed to be treated and have the same effects as shown in subcutaneous 
models.  
Additionally, it is important to determine if human diseased tissues respond in the 
same fashion as those in our representative animal models. As HIFU is now FDA approved 
for ablation of prostate cancer, in cases where the physician is attempting to avoid ablation 
of vital surrounding structures, noting the tissue responses in those areas would be 
beneficial for eventual translation of this combination therapy. Knowing that blood flow 
and vascular permeability are increased and that up-regulation of HS receptors occurs 
could provide greater rationale for use of this combination therapy in clinical scenarios. If 
these effects do not occur, then this combination therapy would likely not achieve its 
desired effect.  
Finally, staging of the treatment should be investigated as it may have additional 
benefits for improving accumulation in heated tumor tissues. It has been shown that 
through vascular effects, the peak accumulation of untargeted water-soluble polymers 
occurs around 5 h post heat treatment [6, 7, 9]. After treatment with hyperthermia for HS-
targeting, the maximal expression of glucose-regulated protein 78 (GRP78) cell surface 
receptors occurs between and 8 and 12 h post heat treatment. Thus, it may be possible to 
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coordinate the maximal accumulation of HS-targeted copolymers with the maximal 
expression of the GRP78 receptors. This, however, would require two heat treatments: one 
to upregulate the receptors and then a second to increase accumulation of polymers. Other 
factors including sensitivity to multiple heat treatments may play a role in the success of 
this delayed injection and dual heat treatment as tumor tissues may respond differently to 
a second heat dose as they become thermotolerant.  
It has been suggested that the use of HPMA-copolymers with covalently attached 
drugs may have better repeated treatments for drug-resistant cancers in comparison to 
delivered drugs with liposomes due to their mechanisms of internalization. The comparison 
of these two delivery vehicles would be useful in a side-by-side study to determine the 
efficacy of multiple treatments in drug-resistant and nonresistant cancers.  
Since this work developed a HIFU system to heat at hyperthermic conditions, this 
system could be leveraged for other scenarios where noninvasive heating would augment 
or improve another therapeutic strategy. For example, HIFU hyperthermia can be used to 
improve the viral translational efficiency of locally delivered adenoviruses.  
Additionally, chemotherapies are considered a last resort therapy when all other 
treatments have been considered. Other therapeutics must be considered instead of 
chemotherapeutics which have harmful side-effects. These therapies could also have 
enhanced effectiveness towards cancerous tissues which has been exposed to 
hyperthermia.  
The work shown in this dissertation has further expanded on previously promising 
research. This research represents progress that will move forward to one day providing 
clinicians with an additional tool for the treatment of advanced localized prostate cancer. 
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With further development suggested here, it may one day be possible to provide this 
treatment to many patients in the effort to eliminate cancers which have begun to invade 
healthy vital tissues before they metastasize. While treatment of prostate cancer was the 
intended motivation of this work, the tools and knowledge developed here can also be 
applied in other scenarios and diseases.  
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Figure A.2: Mass spectroscopy confirmation of APMA-DOTA monomer. 
Expected molecular weight is 693 daltons. Peaks show expected plus one 
hydrogen atom (694 daltons) and plus one sodium atom (716 daltons). 
Apoorva Panda/Dhandehari/APMA-DOTA
m/z

























Figure A.3: Size-exclusion chromatograph of HPMA-
DOTA copolymer after chelation of gadolinium and 
dialysis. Mw = 51 kDa. PDI = 1.67. 











































Figure A.5: Mass spectroscopy of MA-GFLG-DOC monomer. 
Expected molecular weight is 1272 daltons. Second peak is 















Figure A.6: Mass spectroscopy of A) heat shock-targeting and B) 
















Figure A.7: Size-exclusion chromatographs of A) heat shock-
targeted polymer-DOC conjugates and B) untargeted polymer-
DOC conjugates. Polymer characteristics (Mw and PDI) are 
summarized in Table 5.1. 
A 
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Figure A.8: Standard curve of DOC concentrations used to 
determine the amount of drug release from the polymer-drug 
conjugates. Drug content was determined by peak height on 
HPLC and back calculated based on concentration to 
determine DOC wt %. 
  
